Publications

Thomas Karn

Published:

Publication year:

Publications 2024:

Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, Zahm DM, Jackisch C, Mackelenbergh MV, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4+ and expansion of gamma-delta T cells correlate with response to durvalumab in triple negative breast cancer patients. Clin Transl Med. 2024 Apr;14(4):e1617. doi: 10.1002/ctm2.1617.
PMID: 38664548

Shehaj I, Krajnak S, Tahmasbi Rad M, Gasimli B, Hasenburg A, Karn T, Schmidt M, Müller V, Becker S, Gasimli K. Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study. J Cancer Res Clin Oncol. 2024 Apr 3;150(4):174. doi: 10.1007/s00432-024-05699-1.
PMID: 38570343

Dokara-Friedrich ML, Loeffler M, Shehaj I, Tahmasbi-Rad M, Gasimli B, Karn T, Sanhaji M, Becker S, Gasimli K. The clinical relevance of fractional curettage in the diagnostic management of primary endometrial cancer. Gynecol Obstet Invest 2024 Mar 12. doi: 10.1159/000538268. Online ahead of print.
PMID: 38471484


Publications 2023:

Licata L, Barreca M, Galbardi B, Dugo M, Viale G, Gyorffy B, Karn T, Pusztai L, Gianni L, Callari M, Bianchini G. Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. Br J Cancer 2023 Dec;129(12):2025-2033. doi: 10.1038/s41416-023-02477-7. Epub 2023 Nov 7.
PMID: 37935787

Williams T, Schneeweiss A, Jackisch C, Shen C, Weber K, Fasching P, Denkert C, Furlanetto J, Heinmöller E, Schmatloch S, Karn T, Szeto C, van Mackelenbergh M, Nekljudova V, Stickeler E, Soon-Shiong P, Schem C, Mairinger T, Müller V, Marmé F, Untch M, Loibl S. Caveolin gene expression predicts clinical outcomes for early-stage breast cancer patients treated with paclitaxel-based chemotherapy in the GeparSepto trial. Clin Cancer Res 2023 Jul 11;CCR-23-0362. doi: 10.1158/1078-0432.CCR-23-0362.
PMID: 37432976

Fasching PA, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, van Mackelenbergh M, Rabizadeh S, Schem C, Heinmöller E, Müller V, Marmé F, Soon-Shiong P, Nekljudova V, Untch M, Loibl S. Expression of immune-cell activity-related genes is an independent predictor of HER2 negative breast cancer chemotherapy response and prognosis in the GeparSepto trial. Clin Cancer Res 2023 Apr 4:CCR-22-2213. doi: 10.1158/1078-0432.CCR-22-2213.
PMID: 37014668

Reimer F, Bryan S, Legler K, Karn T, Eppenberger-Castori S, Pereira-Veiga T, Wikman H, Witzel I, Müller V, Schmalfeldt B, Milde-Langosch K, Schumacher U, Stürken C, Oliveira-Ferrer L. The Role of the Desmosomal Protein Desmocollin 2 in Tumour Progression in Triple Negative Breast Cancer Patients. Cancer Cell Int. 2023 Mar 16;23(1):47. doi: 10.1186/s12935-023-02896-92023
PMID: 36927383

Gonçalves JPL, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, Fasching PA, Karn T, Marmé F, Müller V, Schem C, Sinn BV, Stickeler E, van Mackelenbergh M, Schmitt WD, Denkert C, Weichert W, Schwamborn K. Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging. Int. J. Mol. Sci. 2023, 24, 2860. https://doi.org/10.3390/ijms24032860
PMID: 36769215


Publications 2022:

Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Merci-Bernstam F, Pusztai L. Molecular differences between younger versus older estrogen receptor positive / human epidermal growth factor receptor-2 negative breast cancers. npj Breast Cancer 2022 Nov 7;8(1):119. doi: 10.1038/s41523-022-00492-0.
PMID: 36344517
GitHub Repository: tkarn/ERposAge and tao-qing/npjYoungVsOld

Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, Müller V, Blohmer J-U, Schem C, Engels K, Marmé F, Fissler-Eckhoff A, Fasching PA, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer 2022 Oct 5;22(1):1040. doi: 10.1186/s12885-022-10109-1.
PMID: 36195836

Blenman K, Marczyk M, Karn T, Qing T, Xiaotong Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim E, Park T, Silber A, Wolf D, Reisenbichler E, Denkert C, Sinn B, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. Clin Cancer Res 2022 Apr 4;clincanres.3215.2021. doi: 10.1158/1078-0432.CCR-21-3215. Online ahead of print.
PMID: 35377948
Including large Supplemental Table - 18 Mb


Publications 2021:

Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Müller V, Taube E, Fasching PA, Schmitt WD, Marmé F, Stickeler E, Sinn B, Jank P, Schem C, Klauschen F, van Mackelenbergh M, Denkert C, Loibl S, Capper D. DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clin Epigenetics 2021 Oct 3;13(1):184. doi: 10.1186/s13148-021-01176-5.
PMID: 34602069

Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm D-M, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
PMID: 34520831

Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching PA, Rüschoff R, Stickeler E, Henke R-P, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne C-H, Marmé F, Schumacher U, Loibl S, Müller V. TGFB-induced factor homeobox 1 (TGIF) as potential tumor suppressor in breast cancer. BMC Cancer 2021 Aug 14;21(1):920. doi: 10.1186/s12885-021-08656-0.
PMID: 34391399

Furlanetto J, Marmé F, Seiler S, Thode C, Untch M, Schmatloch S, Schneeweiss A, Bassy M, Fasching PA, Strik D, Stickeler E, Schem C, Karn T, Grischke E-M, Denkert C, van Mackelenbergh M, Müller V, Nekljudova V, Loibl S. Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomized neo-/adjuvant breast cancer trials. Eur J Cancer 2021 Jun 8;152:193-203. doi: 10.1016/j.ejca.2021.04.038.
PMID: 34116270

Sinn BV, Loibl S, Hanusch C, Zahm DM, Sinn HP, Untch M, Weber K, Karn T, Becker C, Marmé F, Schmitt WD, Müller V, Schem C, Treue D, Stickeler E, Klauschen F, Burchardi N, Furlanetto J, van Mackelenbergh M, Fasching PA, Schneeweiss A, Denkert C. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clin Cancer Res 2021 May 1;27(9):2584-2591. doi: 10.1158/1078-0432.CCR-20-3113
PMID: 33593886

Denkert C, Untch M, Benz W, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn B, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. Ann Oncol 2021 Apr;32(4):500-511. doi: 10.1016/j.annonc.2020.12.016.
PMID: 33418062

Hanker LC, El-Balat A, Drosos Z, Kommoss S, Karn T, Holtrich U, Gitas G, Graeser-Mayer M, Anglesio M, Huntsman D, Rody A, Gevensleben H, Hoellen F. Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer. J Cancer Res Clin Oncol. 2021 May;147(5):1421-1430. doi: 10.1007/s00432-021-03558-x.
PMID: 33660008


Publications 2020:

Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J-U, Zahm D-M, Jackisch c, van Mackelenbergh M, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in TNBC patients. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261.
PMID: 33199511

Rüger A, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé R, Kristina Lübbe K, Sinn BV, Karn T, Stickeler E, Müller V, Schem C, Denkert C, Fasching PA, Nekljudova V, Garfias-Macedo T, Hasenfuß G, Haverkamp W, Loibl S, von Haehling S. Cardiotoxicity in patients with breast cancer: Data from the GeparOcto-GBG 84 trial. J Am Heart Assoc. 2020 Dec;9(23):e018143. doi: 10.1161/JAHA.120.018143.
PMID: 33191846

Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills GB, Maina F, Karn T, Dubey V, Khera L, Raj H, Maina F, Lev S. Synthetic lethal combination uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci Adv 2020 Aug 21;6(34):eaba8968. doi: 10.1126/sciadv.aba8968. Print 2020 Aug. 21 Aug 2020: Vol. 6, no. 34, eaba8968. DOI: 10.1126/sciadv.aba8968
PMID: 32937365

Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020.
PMID: 32841306

Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, Becker C, Blohmer J-U, Marme F, Schmitt WD, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching PA, Jackisch C, Untch M, Schneeweiss A, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early triple negative breast cancer in GeparNuevo. Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015. Epub 2020 May 24.
DOI:https://doi.org/10.1016/j.annonc.2020.05.015
PMID: 32461104
GitHub Repository: tkarn/G9-TMB

Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young B, Hanusch CA, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S. A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res. 2020 Jan 13. pii: clincanres.1954.2019. doi: 10.1158/1078-0432.CCR-19-1954
PMID: 31932495
Supplement
GitHub Repository: tkarn/G5-RNA-Seq

El-Balat A, Karn T, Holtrich U, Becker S, Kommoss S, Györffy B, Anglesio MS, Huntsman DG, Drosos Z, Rody A, Gevensleben H,Hanker L. Histotype-specific analysis of acid ceramidase expression in ovarian cancer. Virchows Arch. 2020 Jun;476(6):855-862. doi: 10.1007/s00428-019-02728-0.
PMID: 31897818


Publications 2019:

Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res., 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z
PMID: 31829264

Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert D, Weber K, Schmatloch S, Camara O, Lück H-J, Huober J, Karn T, von Mackelenbergh M, Marme F, Schem C, Stickeler E, Untch M, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer. 2019 Dec;121(12):1009-1015. doi: 10.1038/s41416-019-0630-3.
PMID: 31728025

Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L. Identification and validation of a novel biologics target in triple negative breast cancer. Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w
PMID: 31624295

Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, Marmé F, Nekljudova V, Schem C, Stickeler E, Willumsen N, Untch M, Müller V. Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the GeparQuinto trial. Cancers 2019, 11, 1186; doi:10.3390/cancers11081186
PMID: 31443252

Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne C-H, Solbach C, Heppner BI, Steiger K, Volkmar Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C Relevance of tumor infiltrating lymphocytes (TILs), PD-1 and PD-L1 in highrisk, nodal-metastasized Breast Cancer Patients of the German Adjuvant Intergroup Node-positive Study (GAIN-1) Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub 2019 May 7.
PMID: 31075727

Schallmoser A, Raab M, Karn T, Königsberger S, Schmidt E, Breitenbach-Koller H, Sänger N. Quantitative Analysis of the sHLA-G Protein in Seminal plasma. Am J Reprod Immunol. 2019 Sep;82(3):e13152. doi: 10.1111/aji.13152
PMID: 31132194

Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational diversity and therapy response in breast cancer – a sequencing analysis in the neoadjuvant GeparSepto trial. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258
PMID: 30979740

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. Int J Cancer 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163
PMID: 30694523


Publications 2018:

El-Balat A, Schmeil I, Gasimli K, Saenger N, Karn T, Ahr A, Becker S, Arsenic R, Holtrich U, Engels K. Claudin-1 is linked to presence of implants and micropapillary pattern in borderline epithelial tumours of the ovary. J Clin Pathol 2018;0:1–5. doi:jclinpath-2018-205292.
PMID: 30171086

Gasimli K, Straussner M, Schmeil I, Abbasova A, Karn T, Winkelmann R, Becker S, El-Balat A. Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumor-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva. Arch Gynecol Obstet. 2018 Nov;298(5):945-950. doi: 10.1007/s00404-018-4887-1.
PMID: 30187190

Stevic I, Müller V, Weber K, Fasching P, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Rezai M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.
PMID: 30301470

El-Balat A, Schmeil I, Karn T, Holtrich U, Mavrova-Risteska L, Rody A, Youssef A, Hanker LC. Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients. In Vivo. 2018 Sep-Oct;32(5):1275-1281. doi: 10.21873/invivo.11377.
PMID: 30150457

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J-U, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Tumor-infiltrating lymphocytes (TILs) and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
PMID: 29233559


Publications 2017:

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2018 Jan;167(1):59-71. doi: 10.1007/s10549-017-4480-5. Epub 2017 Sep 5.
PMID: 28875243

Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, Thill M, Rody A, El-Balat A, Hanker L. Claudin-1 expression in cervical cancer. Mol Clin Oncol. 2017 Nov;7(5):880-884. doi: 10.3892/mco.2017.1391. Epub 2017 Aug 25.
PMID: 29181184

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.
PMID: 28822007

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140
PMID: 28750120
Supplement Material: LINK
GitHub Repository: tkarn/TNBC-TIL

Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G and Schmutzler RK. Germline mutation status, pathological complete response, and disease-free survival rates in triple-negative breast cancer: secondory analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007
PMID: 28715532

Safonov A, Jiang T, Bianchini G, Gyorffy B, Karn T, Hatzis C, Pusztai L. Association between DNA level aberrations and immune cell infiltration in breast cancer. Cancer Research 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478
PMID: 28428277
--- Supplementary-Figures: LINK

El-Balat A, Schmeil I, Karn T, Becker S, Sänger N, Holtrich U, Arsenic R. TFF3 expression as stratification marker in borderline epithelial tumors of the ovary. Pathol Oncol Res. 2018 Apr;24(2):277-282. doi: 10.1007/s12253-017-0240-4. Epub 2017 May 3.
PMID: 28470574

El-Balat A, Sänger N, Karn T, Becker S, Holtrich U, Arsenic R. IMP3 expression in borderline tumors of the ovary. Anticancer Research 2017 Feb;37(2):583-588.
PMID: 28179304

Verma N, Müller A-K, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills G, Karn T, Holtrich U, and Lev S. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents ErbB3-associated resistance via the NEDD4-NDRG1 axis. Cancer Res. 2017 Jan 1;77(1):86-99. doi: 10.1158/0008-5472.CAN-16-1797. Epub 2016 Oct 28.
PMID: 27793840
--- Supplementary-ZIP-File: LINK


Publications 2016:

Karn T, Hatzis C. Genomic Markers ER negative breast cancer. In book: Molecular Pathology of Breast Cancer, pp.283-298. Badve S. & Gökmen-Polar Y. (Editors), Springer Press 2016, ISBN 978-3-319-41759-2, DOI: 10.1007/978-3-319-41761-5_19

Pusztai L, Karn T, Safonov A, Abu-Khalaf M, Bianchini G. New Strategies in Breast Cancer: Immunotherapy. Clinical Cancer Res 2016 May 1;22(9):2105-10.
PMID: 26867935

Hoellen F, Kostara A, Karn T, Holtrich U, El-Balat A, Otto M, Rody A, Hanker L. Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters. Molecular and Clinical Oncology 2016 (5): 422-428.
PMID: 27699037

Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G. Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res. 2016 Jan 15;22(2):337-45. Epub 2015 Sep 30.
PMID: 26423797


Publications 2015:

Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets 2015;15(8):652-64. DOI: 10.2174/156800961508151001101209.
PMID: 26452382

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015 Nov 1;75(21):4494-503. Epub 2015 Sep 11.
PMID: 26363007

El-Balat A, Arsenic R, Sänger N, Karn T, Becker S, Holtrich U, Engels, K. Fascin1 expression as stratification marker in borderline epithelial tumors of the ovary. J Clin Pathol 2016 Feb;69(2):142-8. Epub 2015 Sep 11.
PMID: 26362828

Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Holtrich U, Becker S, Karn T. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Research Treatm 2015 Aug;152(3):667-73. Epub 2015 Jul 21.
PMID: 26195120
--- PDF WITHOUT Supplementary Files: LINK

Karn T, Gluz O. Genexpressionsprofile zur Risikoabschätzung und Prädiktion des Therapieansprechens beim Mammakarzinom. In: Tumorbiologie und Diagnostik des primären Mammakarzinoms. Vetter M, Kantelhardt E-J. (Hrsg.), UNI-MED Science, 1. Auflage 2015, ISBN 978-3-8374-1492-9. p. 30-42
--- Ganzes Buch

Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C. Genomic Predictor of Residual Risk of Recurrence after Adjuvant Chemotherapy and Endocrine Therapy in High Risk Estrogen Receptor Positive Breast Cancers. Breast Cancer Res Treat 2015 Feb;149(3):789-97. Epub 2015 Feb 5.
PMID: 25651779
--- PDF WITHOUT Supplementary Files: LINK

Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S. PYK2 sustains endosomal-derived receptor signaling and enhances epithelial-to-mesenchymal transition. Nat Commun. 2015 Feb 4;6:6064. doi: 10.1038/ncomms7064.
PMID: 25648557


Publications 2014:

Karn T, Rody A, Müller V, Schmidt M, Becker S, Holtrich U, Pusztai L. Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer. Genomics Data. 2014, 2:354–356. doi:10.1016/j.gdata.2014.09.014. ONLINE-LINK: http://dx.doi.org/10.1016/j.gdata.2014.09.014
PMID: 26484129

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther. 2014 Nov 28;7:2205-13. doi: 10.2147/OTT.S65344
PMID: 25506225

Sänger N, Engels K, Graf A, Ruckhäberle E, Effenberger K, Fehm T, Holtrich U, Becker S, Karn T. Molecular markers as prognostic factors in DCIS and small invasive breast cancers. Geburtsh Frauenheilk. 2014; 74: 1016–1022. doi: 10.1055/s-0034-1383033
PMID: 25484376
--- Re-Publication in: Senologie 2015; 12: 24–30. DOI http://dx.doi.org/10.1055/s-0034-1399264 LINK

Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G. Expression of Secreted Protein Acidic and Rich in Cysteine (SPARC) is Predictive for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Oncol. 2015 Jan;26(1):95-100. doi: 10.1093/annonc/mdu487
PMID: 25355716

Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer Int J Cancer. 2014 Oct 1. doi: 10.1002/ijc.29247. [Epub ahead of print]
PMID: 25274406

Sänger N, Ruckhäberle E, Györffy B, Engels K, Heinrich T, Fehm T, Graf A, Holtrich U, Becker S, Karn T. Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. Mol Oncol. 2015 Jan;9(1):58-67. doi: 10.1016/j.molonc.2014.07.016. Epub 2014 Jul 31.
PMID: 25131496
--- PDF WITHOUT Supplementary Files: LINK

Keinan O, Kedan A, Gavert N, Selitrennik M, Kim S, Karn T, Becker S, Lev S. The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis. J Cell Sci. 2014 Nov 1;127(21):4740-9. doi: 10.1242/jcs.155648. Epub 2014 Sep 1.
PMID: 25179602
--- Supplementary Information: LINK

Sänger N, Ruckhäberle E, Bianchini G, Heinrich T, Milde-Langosch K, Müller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S, Karn T. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer Mol Oncol. 2014 Oct;8(7):1196-207. doi: 10.1016/j.molonc.2014.04.003. Epub 2014 Apr 15.
PMID: 24785095
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

Milde-Langosch K, Karn T, Schmidt M, zu Eulenburg C, Oliveira-Ferrer L, Wirtz RM, Schumacher U, Witzel I, Schütze D, Müller V. Prognostic relevance of glycosylation-associated genes in breast cancer Breast Cancer Res and Treatm. 2014 Jun;145(2):295-305. doi: 10.1007/s10549-014-2949-z. Epub 2014 Apr 16.
PMID: 24737166


Publications 2013:

Karn T. High throughput gene expression and mutation profiling: current methods and future perspectives. Breast Care (Basel) 2013 Dec;8(6):401-6. doi: 10.1159/000357461.
PMID: 24550747

Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res. 2013 Sep 23;15(5):R86. [Epub ahead of print]
PMID: 24060333

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G. Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9.
PMID: 23955546

von Minckwitz G, Schmitt W, Loibl S, Müller BM, Blohmer JU, Sinn B, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstößer E, Fasching PA, Karn T, Mueller V, Jackisch C, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clinical Cancer Res 2013 Aug 15;19(16):4521-4531. Epub 2013 Jun 27.
PMID: 23812670

Hanker LC, Karn T, Holtrich U, Gätje R, Rody A, Heinrich T, Ruckhäberle E, Engels K. Acid Ceramidase (AC) - A Key Enzyme of Sphigolipid Metabolism - Correlates With Better Prognosis in Epithelial Ovarian Cancer Int J Gynecol Pathol. 2013 2013 May;32(3):249-57.
PMID: 23518908

Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The prognostic impact of age in patients with triple negative breast cancer. Breast Cancer Res and Treatm. 2013 Apr;138(2):591-9.
PMID: 23460246

Karn T. Combination of Genomic and Transcriptomic Assays Gives New Insights in Breast Cancer Biology. Breast Care 2013;8:84-87 (DOI:10.1159/000348467)

Kaufmann M, Karn T. Anwendung und Kostenfolgen der individualisierten Medizin: Diagnose- und Therapieoptionen in der gynäkologischen Onkologie. Frankfurter Forum : Diskurse April 2013, Heft 7, 6-13 (ISSN 2190-7366)
   Ganzes Heft
   Weblink zum Artikel
   Weblink zum Heft

Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D, Rausch A, Jänicke F, Milde-Langosch K, Müller V. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J Cancer Res Clin Oncol. 2013 May;139(5):809-16.
PMID: 23392859

Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckhäberle E, Gevensleben H, Rody A. Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Research 2013 Feb;33(2):371-7.
PMID: 23393326

Schütze D, Milde-Langosch K, Witzel I, Rody A, Karn T, Schmidt M, Choschzick M, Jänicke F, Müller V. Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. J Cancer Res Clin Oncol. 2013 May;139(5):747-54.
PMID: 23358720

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T. Prognostic evaluation of the B-cell/IL-8 metagene in different intrinsic breast cancer subtypes Breast Cancer Research and Treatment 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.
PMID: 23242614
--- Print-Version-PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK


Publications 2012:

Karin Milde-Langosch, Thomas Karn, Volkmar Müller, Isabell Witzel, Achim Rody, Markus Schmidt, Ralph M. Wirtz. Validity of the proliferation markers Ki67, TOP2A and RacGAP1 in molecular subgroups of breast cancer Breast Cancer Research and Treatment 2013 Jan;137(1):57-67. doi: 10.1007/s10549-012-2296-x. Epub 2012 Nov 8.
PMID: 23135572

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer. Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.
PMID: 23079573

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 2012 Sep 4;107(6):956-60. doi: 10.1038/bjc.2012.353. Epub 2012 Aug 14.
PMID: 22892393

Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van 't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis I, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olsen JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John E, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G; kConFab Investigators, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Arias Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet. 2012 Sep 1;21(17):3926-39. Epub 2012 Apr 24.
PMID: 22532573

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012 May 1;18(9):2695-703
PMID: 22351685

Kaufmann M, Karn T, Ruckhäberle E. Controversies Concerning the Use of Neoadjuvant Systemic Therapy for Primary Breast Cancer World J Surg. 2012 Jul;36(7):1480-5.
PMID: 22278605


Publications 2011:

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A. Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures (2011) PLoS ONE. 2011;6(12):e28403. Epub 2011 Dec 29.
PMID: 22220191
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gaetje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.
PMID: 21741824
--- Print-Version WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. A Clinically Relevant Gene Signature in Triple Negative and Basal Like Breast Cancer. Breast Cancer Research 2011, 13:R97.
PMID: 21978456
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

M. Kaufmann, G. von Minckwitz, E.Mamounas, D. Cameron, L. Carey, M. Cristofanilli, C. Denkert, W. Eiermann, M. Gnant, J.R. Harris, T. Karn, C. Liedtke, D. Mauri, R. Rouzier, E. Ruckhäberle, V. Semiglazov, W.F. Symmans, A. Tutt, L. Pusztai. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy (NST) in Primary Breast Cancer. Ann Surg Oncol 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23.
PMID: 22193884

Karn T, Ruckhaeberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gaetje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat 2011, 130:409–420.
PMID: 21203899
--- Editorial Harbeck: LINK
--- JCO Editorial Harbeck & Rody: LINK
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary Material: LINK

Hanker L, Karn T, Mavrova, L, Ruckhaeberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I. SATB1 gene expression and breast cancer prognosis. Breast 2011 Aug;20(4):309-13. Epub 2010 Oct 25.
PMID: 20980149

M. Kaufmann, L. Pusztai, F. Cardoso, M. Dietel, L. Edler, M. Hahn, W. Jonat, T. Karn, H. Kreipe, S. Loi, G. von Minckwitz, A. Rody, H. P. Sinn, M. J. van de Vijver. Use of Standard Markers and Incorporation of Molecular Markers into Breast Cancer Therapy: Recommendations from an International Expert Panel. Cancer 2011 Apr 15;117(8):1575-82.
PMID: 21472705


Publications 2009-2010:

Karn T, Rody A, Ruckhaeberle E, Gaetje R, Kaufmann M. Brustkrebs: Auf dem Weg zu einer personalisierten Therapie. Forschung Frankfurt 2/2010:32-36. --- High Resolution Proof (errors): LINK

Ruckhaeberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A. Prognostic impact of thymidine phosphorylase expression in breast cancer – comparison of microarray and immunohistochemical data. Eur J Cancer 2010; 46: 549–557. Epub 2009 Dec 18.
PMID: 20022486
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

Hanker L, Karn T, Rody A, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M. Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res Treat 2010 Aug;122(3):765-75. Epub 2009 Nov .
PMID: 19898932
--- PDF WITHOUT Supplementary Files: LINK

Karn T, Holtrich U, Ruckhäberle E, Hanker L, Schlieter A, Solbach C, Gätje R, Kaufmann M, Rody A. Methodischer Bias retrospektiver Follow-Up-Untersuchungen und sein Einfluß auf die Erhebung von Qualitätssicherungsdaten. Geburtsh Frauenheilk 2010; 70: 41–46.

Ruckhaeberle E, Karn T, Hanker L, Schwarz J, Schulz-Knappe P, Kuhn K, Böhm G, Selzer S, Neukum E, Engels K, Holtrich U, Kaufmann M, Rody A. Breast Cancer Proteomics – Differences in protein expression between ER positive and negative tumours identified by Tandem Mass Tag Technology. Breast Care Breast Care 2010;5:7–10.
PMID: 22619634

Gaetje R, Holtrich U, Engels K, Ruckhaeberle E, Rody A, Karn T, Kaufmann M. Does Sphingosine Kinase 1 (SPHK1) Play a Role in Endometriosis? Geburtsh Frauenheilk 2009; 69: 935–939.

Ruckhäberle E, Holtrich U, Engels K, Hanker L, Gaetje R, Metzler D, Karn T, Kaufmann M, Rody A. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 2009 Dec;12(6):502-13.
PMID: 19905902

Rody A, Karn T, Holtrich U, Kaufmann M. Das Stammzellkonzept der Mamma. Der Onkologe 2009 DOI 10.1007/s00761-009-1619-y [Epub ahead of print].

Karn T, Metzler D, Ruckhaeberle E, Hanker L, Solbach C, Ahr A, Gaetje R, Schmidt M, Holtrich U, Kaufmann M, Rody A. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix microarrays to stratify distinct types of clinical breast cancer. Breast Cancer Res Treat 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.
PMID: 19455418
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary Material: LINK

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favourable prognosis in estrogen receptor negative and HER2 positive breast cancers. Breast Cancer Res. 2009 Mar 9;11(2):R15. [Epub ahead of print]
PMID: 19272155
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary-ZIP-File: LINK

Rody A, Karn T, Pobitschka F, Ruckhäberle E, Solbach C, Gehrmann M, Ahr A, Hanker L, Gaetje R, Holtrich U, Kaufmann M. Prognostic value of gene signatures and tumorbiological characteristics in breast cancer patients treated with anthracycline containing chemotherapy. Geburtshilfe und Frauenheilkunde 2008; 68: 1171–1177.

Ruckhäberle E, Karn T, Rody A., Hanker L, Gaetje R, Metzler D, Holtrich U, Kaufmann M. Gene Expression of Ceramide Kinase, Galactosyl Ceramide Synthase and Ganglioside GD3 Synthase is associated with Prognosis in Breast Cancer. J Cancer Res Clin Oncol. 2009 Aug;135(8):1005-13. [Epub 2009 Jan 6].
PMID: 19125296


Publications 2007-2008:

Rody A., Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gaetje R, Holtrich U, Kaufmann M. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers – results of a large scale microarray analysis. Eur J Cancer 2009 Feb;45(3):405-13. Epub 2008 Dec 4.
PMID: 19054665
--- PDF WITHOUT Supplementary Files: LINK
--- Supplementary Material: LINK

Gaetje R, Holtrich U, Engels K, Rody A., Karn T, Kaufmann M. Expression of Cytokeratin 8 (CK8) in Human Endometrium and Endometriosis. Geburtsh Frauenheilk 2008; 68, 801-804.

Rody A., Karn T, Ruckhäberle E, Hanker L, Gaetje R, Holtrich U, Kaufmann M. Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer. Eur J Cancer 2008 Sep;44(13):1789-92. Epub 2008 Aug 6.
PMID: 18691884

Ruckhäberle E, Karn T, Hanker L, Gaetje R, Metzler D, Holtrich U, Kaufmann M, Rody A. Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 2009 Jan;135(1):81-90. Epub 2008 Jun 17.
PMID: 18560890

Gaetje R, Holtrich U, Engels K, Kissler S, Rody A, Karn T, Kaufmann M. Differential expression of claudins in human endometrium and endometriosis. Gynecological Endocrinology 2008 Aug;24(8):442-9.
PMID: 18850381

Rody A, Karn T, Holtrich U, Kaufmann M. "Stem cell like" breast cancers-A model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):11-5. Epub 2008 Apr 15.

Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gaetje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 2009 Feb;113(3):457-66. Epub 2008 Mar 14.
PMID: 18340528

Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008 Nov;112(1):41-52. Epub 2007 Dec 4.
PMID: 18058224

Minckwitz, G. von; Eidtmann, H.; Groner, B.; Harbeck, N.; Huober, J.; Karn, T.; Komor, M.; Lenhard, M.; Loibl, S.; Martin, B.; Müller, V.; Niederacher, D.; Rody, A.; Roller, M.; Schrauder, M.; Thomssen, C.; Kaufmann, M. Translational Research for Breast Cancer – Workshop for new research ideas at the Biedenkopf Symposium XIII of the Banss Foundation. Geburtsh Frauenheilk 2008; 68: 1160–1165.

Rody A, Karn T, Solbach C, Gatje R, Munnes M, Kissler S, Ruckhaberle E, von Minckwitz G, Loibl S, Holtrich U, Kaufmann M. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 16(3),235-40. Epub 2007 Apr 20.
PMID: 17449250

Gaetje R, Holtrich U, Engels K, Kourtis K, Cikrit E, Kissler S, Rody A, Karn T, Kaufmann M. Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosis Gynecological Endocrinology October 2007; 23(10), 567-573.
PMID: 17952761

Gaetje R, Holtrich U, Karn T, Cikrit E, Engels K, Rody A, Kaufmann M. Characterization of WNT7A expression in human endometrium and endometriotic lesions. Fertil Steril. 2007 Dec;88(6):1534-40.
PMID: 17588571

Rody A, Holtrich U, Gatje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhaberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann. Poor Outcome in Estrogen Receptor-PositiveBreastCancers Predicted by Loss of Plexin B1. Clin Cancer Res. 2007 Feb 15;13(4):1115-22.
PMID: 17317819

Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28.
PMID: 17010609

Gaetje R, Holtrich U, Engels K, Kissler S, Rody A, Karn T, Kaufmann M. Endometriosis may be generated by mimicking the ontogenetic development of the female genital tract. Fertil Steril. 2007 Mar;87(3):651-6. Epub 2006 Nov 29.
PMID: 17140576

Gaetje R, Mavrova-Risteska L, Zangos S, Karn T, Kissler S, Vogl T, Kaufmann M. Clinical Outcome after Myomectomy versus Uterine Artery Embolization for Uterine Fibroids. Geburtsh Frauenheilk 2007, 67:748-752.


Publications 2003-2006:

Rody A, Karn T, Gatje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhaberle E, Holtrich U, Kaufmann M, Ahr A. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol. 2006, 128(2):76-81.

Rody A, Karn T, Kaufmann M: Predictive and Prognostic Markers in Breast Cancer Treatment - Presentations at the 28th San Antonio Breast Cancer Symposium 2005. Breast Care 2006;1:118-122

Ahr A, Holtrich U, Karn T, Reitter A, Rody A, Kaufmann M, Gatje R. Identification of preeclampsia by cDNA-gene expression profiling in human placentas and serum -- a pilot study Zentralbl Gynakol. (2006) 128(3):138-42.

Diallo R, Rody A, Jackisch C, Ting E, Schaefer KL, Kissler S, Karn T, Geddert H, Engels K, Kaufmann M, Gabbert HE, Shroyer KR, Poremba C. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. Human Pathol. (2006) 37(2):205-11.
PMID: 16426921

Rody, A., Holtrich, U., Solbach, C., Kourtis, K., von Minckwitz, G., Engels, K., Kissler, S., Gatje, R., Karn, T., Kaufmann, M. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker for premalignant lesions Endocr Relat Cancer, (2005) 12, 903-916.
PMID: 16322330
--- Skliris and Murphy, Journals Club: LINK

Karn, T., Ahr, A., Holtrich, U., Kaufmann, M. Identification of high risk breast-cancer patients by DNA chip technology. In: Leonard R, Polychronis A, Miles A (ed.) The Effective Management of Breast Cancer - Second edition, UK Key Advances in Clinical Practice Series, Aesculapius Medical Press (London); 148-156.(2005)


Publications 1999-2002:

Ahr, A., Karn, T., Solbach, C., Seiter, T., Strebhardt, K., Holtrich, U., Kaufmann, M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet, (2002) 359, 131-32.
PMID: 11809257

Ahr, A., Holtrich, U., Karn, T., Kaufmann, M. CORRESPONDENCE: Gene-expression profiling and identification of patients at high risk of breast cancer. Lancet, (2002), 360, 173-174.

Ahr, A., Holtrich, U., Solbach, C., Scharl, A., Strebhardt, K., Karn, T., Kaufmann, M. Molecular classification of breast cancer patients by gene expression profiling J. Pathol., (2001) 195, 312-320.
PMID: 11673828

Ahr, A., Holtrich, U., Solbach, C., Scharl, A., Strebhardt, K., Karn, T., Kaufmann, M. Molekularbiologische Klassifikation von Hochrisiko-Patientinnen beim primären Mammakarzinom durch Genexpressionsanalysen Geburtshilfe und Frauenheilkunde (2001) 61, 954-963.

Holtrich, U., Wolf, G., Yuan, Y., Bereiter-Hahn, J., Karn, T., Weiler, M., Kauselmann, G., Rehli, M., Andreesen, R., Kaufmann, M., Kuhl, D., Strebhardt, K. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene (2000) 19, 4832-4839.
PMID: 11039900

Ahr, A., Holtrich, U., Karn, T., Solbach, C., Göhring, U.-J., Costa, S.D., Scharl, A., Strebhardt, K., Kaufmann, M. Detektion differentiell exprimierter Gene beim primären Mammakarzinom mittels cDNA-Array-Hybridisierung Geburtshilfe und Frauenheilkunde (2000) 08, 412-417.


Publications 1992-1998:

Karn, T., Hock, B., Holtrich, U., Adamski, M., Strebhardt, K. & Rübsamen-Waigmann, H. Nef proteins of distinct HIV-1 or -2 isolates differ in their binding properties for HCK - isolation of a novel Nef binding factor with characteristics of an adaptor protein. Virology (1998)246, 45-52
PMID: 9656992

Hock, B., Böhme, B., Karn, T., Kaibuchi K., Yamamoto, T., Holtrich, U., Rübsamen-Waigmann, H. & Strebhardt, K. : PDZ-domain mediated interaction of Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF-6 depends on the kinase activity of the receptor Proc. Natl. Acad. Sci. USA.(1998), 95, 9779-9784
PMID: 9707552

Hock, B., Böhme, B., Karn, T., Feller, S., Rübsamen-Waigmann, H. & Strebhardt K. Tyrosine-614, the major autophosphorylation site of the recepeptor tyrosine kinase HEK2 functions as multi docking site for SH2-domain mediated interactions Oncogene (1998), 17, 255-260.
PMID: 9674711

Karn, T., Holtrich, U., Wolf, G., Hock, B., Strebhardt, K. & Rübsamen-Waigmann, H. Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis Oncol. Rep. (1997) 4, 505-510.
PMID: 21590086

Holtrich, U., Wolf, G., Bräuninger, A., Karn, T., Böhme, B., Rübsamen-Waigmann, H. & Strebhardt, K. Induction and downregulation of human PLK, a serine/threonine kinase expressed in proliferating cells and tumors Proc. Natl. Acad. Sci. USA (1994), 91, 1736-1740.
PMID: 8127874

Kobelt, D., Karn, T., Hock, B., Holtrich, U., Bräuninger, A., Wolf, G., Strebhardt, K. & Rübsamen-Waigmann, H. Human and Xenopus MO15 mRNA are highly conserved but show different patterns of expression in adult tissues Oncol. Rep. (1994) 1, 12691-1275.
PMID: 21607529

Strebhardt, K., Holtrich, U., Bräuninger, A., Karn, T., Böhme, B., Doermer, A. & Rübsamen-Waigmann, H. Oncogenic alterations in primary human lung tumors (Review) Oncol. rep. (1994), 1: 195-201.

Karn, T., Holtrich, U., Bräuninger, A., Böhme, B., Wolf, G., Rübsamen-Waigmann, H. & Strebhardt, K. Structure, expression and chromosomal mapping of TKT from man and mouse, a new subclass of receptor tyrosine kinases with a factor VIII-like domain Oncogene (1993), 8, 3433-3440.
PMID: 8247548

Bräuninger, A., Karn, T., Strebhardt, K. & Rübsamen-Waigmann, H. Characterization of the human CSK locus Oncogene (1993), 8, 1365-1369.
PMID: 7683131

Hradetzky, D., Schimpf, A., Karn, T., Strebhardt, K. & Rübsamen-Waigmann, H. Taq cycle sequencing of plasmid DNA purified by various procedures BTE (1992), 9, 471-472.


Talks / Posters:

Thomas Karn

International Meetings: National Meetings:

SABCS - San Antonio Breast Cancer Symposium:

Knappskog S, Helwa R, Rachakonda K, Gansmo LB, Carsten Denkert C, Yates LR, Solbach C, Untch M, Sinn B, Litmeyer A-S, Ataseven B, Huober J, David C. Wedge DC, Thomas Karn T, Nikolaienko O, Marmé F, Fasching PA, Eikesdal HP, Stickeler E, Schem C, Jank P, van Mackelenbergh M, Müller V, Felder B, Holtschmidt J, Campbell PJ, Loibl S, Lønning PE. CDH1 mutations predict resistance to neoadjuvant taxane therapy. SABCS 2023 .

Huebner H, Ruebner M, Schneeweiss A, Denkert C, Sinn HP, Braun M, Karn T, Sinn B, Zahm D-M, Thomalla J, Huober J, Hanusch C, Untch M, Solbach C, Link T, Filmann N, Rey J, Holtschmidt J, Loibl S, Fasching PA. Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial. SABCS 2023 .

Denkert C, Schneeweiss A, Rey J, Hattesohl A, Karn T, Braun M, Jank P, Huober J, Sinn H-P, Zahm D-M, Hanusch C, Marmé F, Furlanetto J, Thomalla J, Blohmer J, van Mackelenbergh M, Stiewe T, Staib P, Jackisch C, Teply-Szymanski J, Fasching PA, Sinn B, Untch M, Weber K, Loibl S. Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy. SABCS 2022 Spotlight Poster Discussion PD4-02. --- Poster: LINK

Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J-U, Zahm D-M, Jackisch C, van Mackelenbergh M, Thomalla J, Marmé F, Huober J, Volkmar Müller V, Schem c, Müller A, Stickeler E, Biehl K, PAF, Untch M, Loibl S, Denkert C, Seliger B Immunological effect of durvalumab in TNBC. SABCS 2022 Spotlight Poster Discussion PD9-04. --- Poster: LINK

Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older estrogen receptor positive / human epidermal growth factor receptor-2 negative breast cancers with low proliferation. SABCS 2022 Spotlight Poster Discussion PD9-09. --- Poster: LINK

Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Karn T, Schneeweiss A, Sinn B, Fehm T, Denkert C, Müller V, Litmeyer AS, Schem C, Paul Jank P, Marmé F, Furlanetto J, Fasching PA, Stickeler E, Ortmann O, van Mackelenbergh M, Nekljudova V, Loibl S. Immunological markers in patients with breast cancer occurring during pregnancy –results from GBG BCP study. SABCS 2021. --- Poster: LINK

L. Licata, B. Galbardi, B. Gyorffy, T. Karn, L. Sica, A. Rognone, P. Zucchinelli, D. Aldrighetti, S.Zambelli, L. Gianni, G. Bianchini. Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes. SABCS 2019 P4-05-09. --- Poster: LINK

Terence Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher Szeto, Marion van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Barbara Fleige, Volkmar Müller, Frederik Marmé, Michael Untch, Sibylle Loibl. Caveolin Gene Expression Predicts for Response and Clinical Outcomes for Patients Treated with Preoperative Paclitaxel-based Chemotherapy Regimens in Early Stage Breast Cancer (BC). SABCS 2019 P1-10-01. --- Poster: LINK

Peter A Fasching; Carsten Denkert; Stephen Benz; Karsten Weber; Christopher Szeto; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch; Christian Jackisch; Thomas Karn; Hans Peter Sinn; Mathias Warm; Marion van Mackelenbergh; Sharooz Rabizadeh; Christian Schem; Ernst Heinmöller; Volkmar Müller; Frederik Marmé; Patrick Soon-Shiong; Valentina Nekljudova; Michael Untch; Sibylle Loibl. Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - an analysis of the GeparSepto trial. Poster Discussion SABCS 2019 PD5-08. --- Poster: LINK

Christopher Szeto; Carsten Denkert; Peter A Fasching; Stephen Benz; Karsten Weber; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch; Christian Jackisch; Thomas Karn; Hans Peter Sinn; Mathias Warm; Marion van Mackelenbergh; Shahrooz Rabizadeh; Christian Schem; Ernst Heinmöller; Volkmar Müller; Frederik Marmé; Patrick Soon-Shiong; Valentina Nekljudova; Michael Untch; Sibylle Loibl. Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations. SABCS 2019 P6-10-04. --- Poster: LINK

Karolin Fröhlich, Thorsten Plösch, Fenja Seither, Volkmar Müller, Thomas Karn, Elmar Stickeler, Christian Schem, Christine Solbach, Amelie Lupp, Rikst Nynke Verkaik-Schakel, Gitta Turowski, Peter Mallmann, Marion van Mackelenbergh, Bruno Sinn, Valentina Nekljudova, Carsten Denkert, Pamela Schittler, Udo Markert, Sibylle Loibl. Histological and epigenetic analyses of placentas from breast cancer patients. SABCS 2019 P4-04-08. --- Poster: LINK

Thomas Karn, Carsten Denkert, Bruno V. Sinn, Karsten E. Weber, Valentina Nekljudova, Achim Rody, Tobias Meissner, Christos Hatzis, Ahmed El-Balat, Sven Becker, Christine Solbach, Michael Untch, Andreas Schneeweiss, Gunter von Minckwitz, Sibylle Loibl, Lajos Pusztai, Uwe Holtrich. Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene. SABCS 2018. Cancer Res 2019, 79(4) Supplement P3-10-01. DOI: 10.1158/1538-7445.SABCS18-P3-10-01 --- Poster: LINK

Loibl S, Sinn BV, Karn T, Untch M, Treue D, Sinn HP, Weber K, Hanusch C, Fasching P, Huober J, Zahm M, Jackisch C, Thomalla J, Blohmer JU, Marmé F, Klauschen F, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. mRNA Signatures Predict Response to Durvalumab Therapy in Triple Negative Breast Cancer – Results of the Translational Biomarker Programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. SABCS 2018. Cancer Res 2019, 79(4) Supplement PD2-07. DOI: 10.1158/1538-7445.SABCS18-PD2-07 --- Poster: LINK

Massa C, Schneeweiss A, Karn T, Hanusch C, Blohmer J, Fasching P, Jackisch C, van Mackelenbergh M, Marmé F, Müller V, Schem C, Stickeler E, Huober J, Weber K, Untch M, Denkert C, Loibl S, Mueller A, Biehl K, Seliger B. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - results from the prospectively randomised GeparNuevo trial. SABCS 2018. Cancer Res 2019, 79(4) Supplement P4-06-01. DOI: 10.1158/1538-7445.SABCS18-P4-06-01 --- Poster: LINK

Sinn BV, Loibl S, Karn T, Untch M, Kunze C, Weber K, Treue D, Wagner K, Hanusch C, Klauschen F, Fasching PA, Huober J, Zahm M, Jackisch C, Thomalla J, Blohmer JU, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Pre-therapeutic PD-L1 expression and dynamics of KI67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. SABCS 2018. Cancer Res 2019, 79(4) Supplement PD5-05. DOI: 10.1158/1538-7445.SABCS18-PD5-05 --- Poster: LINK

Thomas Karn, Tobias Meissner, Karsten E. Weber, Bruno Sinn, Carsten Denkert, Jan Budczies, Valentina Nekljudova, Peter A. Fasching, Uwe Holtrich, Christian Schem, Christine Solbach, Arndt Hartmann, Christoph Röcken, Michael Untch, Brandon M Young, Scooter Willis, Brian Leyland-Jones, Gunter von Minckwitz, Sibylle Loibl. Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment. SABCS 2017. Cancer Res 2018, 78(4) Supplement P2-09-02. DOI: 10.1158/1538-7445.SABCS17-P2-09-02. --- Poster: LINK

Furlanetto J, Thode C, Huober J, Denkert C, Bassy M, Hanusch C, Jackisch C, Kümme S, Schneeweiss A, Untch M, Fasching PA, Karn T, Marmé F, van Mackelenbergh M, Müller V, Schem C, von Minckwitz G, Strik D, Nekljudova V, Loibl S Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC). SABCS 2017. Abstract #. --- Poster: LINK

Sinn BV, Weber K, Denkert C, Fasching PA, Schmitt WD, Karn T, Ingold-Heppner B, van Mackelenbergh M, Symmans WF, Marmé F, Taube E, Müller V, Schem C, Kunze K, Stickeler E, Pfitzner BM, von Minckwitz G, Loibl S HLA class I expression is associated with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer. SABCS 2017. Abstract #. --- Poster: LINK

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Holtrich U, Becker S, Bianchini G, Pusztai L. Immune sculpting of the triple negative breast cancer genome. SABCS 2016 [S1-07], General Session Oral Presentation. --- Slides: LINK

van Mackelenbergh M, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer J-U, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S. Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients – a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. SABCS 2016 [P1-09-11]. --- Poster: LINK

van Rossum AGJ, Schouten PC, Weber EK, Nekljudova V, Denkert C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S and Marmé F. BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study). SABCS 2015 [P3-07-28].

Thomas Karn, Lajos Pusztai, Cornelia Liedtke, Giampaolo Bianchini, Balazs Györffy, Christos Hatzis, Achim Rody, Volkmar Müller, Marcus Schmidt, Uwe Holtrich, Sven Becker. Gene expression associated with poor prognosis of young TNBC patients. San Antonio Breast Cancer Symposium 2014. Cancer Res 2015;75(9 Suppl): Abstract P2-05-04. DOI: 10.1158/1538-7445. SABCS14-P2-05-04.

Giampaolo Bianchini, Eugenia Galeota, Tingting Jiang, Maurizio Callari, Milvia Zambetti, Takayuki Iwamoto, Thomas Karn, Christos Hatzis, Lajos Pusztai, Luca Gianni. The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes. San Antonio Breast Cancer Symposium 2014.Cancer Res 2015;75(9 Suppl): Abstract P2-03-05. DOI: 10.1158/1538-7445. SABCS14-P2-03-05.

Stefanie Avril, Gunter von Minckwitz, Sibylle Gündisch, Stephan Gade, Katharina Malinowsky, Peter Fasching, Thomas Karn, Arndt Hartmann, Michael Untch, Carsten Denkert, Karl-Friedrich Becker, Sibylle Loibl. Assessment of phosphorylated HER2 protein as predictive biomarker to stratify anti-HER2 treatment in HER2 non-amplified patients – a translational study in the GeparQuattro and GeparQuinto trials. San Antonio Breast Cancer Symposium 2014. San Antonio Breast Cancer Symposium 2014.Cancer Res 2015;75(9 Suppl): Abstract P3-06-36. DOI: 10.1158/1538-7445. SABCS14-P3-06-36.

Liedtke C, Karn T, Gluz O, Becker S, Pusztai L, Holtrich U, Rody A. Systematic analysis of molecular subgroups and age in patients with TNBC. San Antonio Breast Cancer Symposium 2013.

Bianchini G, Rossi CM, Iwamoto T, Karn T, Kelly CM, Pusztai L, Gianni. Expression of immune checkpoint related genes are prognostic in untreated breast cancer. San Antonio Breast Cancer Symposium 2013.

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Rody A, Wirtz R, Jänicke F, Müller V. Role of uPA and PAI-1 as prognostic factors in molecular subtypes of breast cancer. San Antonio Breast Cancer Symposium 2013, P6-06-44.

Balázs Gyorffy, Thomas Karn, Zsófia Sztupinszki, Boglárka Weltz, Volkmar Müller, Lajos Pusztai. Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer. San Antonio Breast Cancer Symposium 2013.

Karn T, Hatzis C, Symmans WF, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Hanker L, Heinrich T, Holtrich U, Kaufmann M, Becker S, Rody A. SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. San Antonio Breast Cancer Symposium 2012, P2-10-17.

Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, v. Minckwitz G, Denkert C. Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. San Antonio Breast Cancer Symposium 2012, P3-06-01.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Schmidt M, Müller V, Gätje R, Hanker L, Ahr A, Holtrich U, Rody A, Kaufmann M. Prognostic and Predictive Predictors for Triple Negative Breast Cancer. SABCS 2011 Poster Discussion PD03-02

A. Rody, U. Holtrich, E. Ruckhaeberle, J. Radosa, I. Juhasz-Boess, E.F. Solomayer, M. Kaufmann, T. Karn. Relevance of an IL-8/B-cell gene signature identified from triple negative breast cancer (TNBC) in different intrinsic breast cancer subtypes. SABCS 2011 P2-12-11

Ruckhäberle E, Müller V, Schmidt M, Sänger N, Gätje R, Hanker L, Ahr A, Holtrich U, Rody A, Karn T, Kaufmann M. Prognostic impact of RANK, RANKL, and OPG gene expression in ER positive breast cancer. SABCS 2011 P3-01-12

A Rody, T Karn, C Liedtke, L Pusztai, E Ruckhaberle, L Hanker, R Gaetje, C Solbach, A Ahr, D Metzler, M Schmidt, V Muller, U Holtrich, and M. Kaufmann. Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer. Cancer Research April 26, 2011 70:S5-5; doi:10.1158/0008-5472.SABCS10-S5-5. General Session Oral Presentation.

Lars Hanker, Thomas Karn, Eugen Ruckhaeberle, Loreta Mavrova-Risteska, Volkmar Müller, Uwe Holtrich, Achim Rody, Manfred Kaufmann. Analysis of the prognostic impact of SATB1 gene expression with respect to ER status in breast cancer. SABCS 2010.

A. Rody, T. Karn, C. Solbach, E. Ruckhaeberle, L. Hanker, V. Mueller, M. Schmidt, R. Gaetje, U. Holtrich, and M. Kaufmann. The Luminal B Marker NHERF1 Predicts Endocrine Resistance. Cancer Research February 10, 2010 69:3164; doi:10.1158/0008-5472.SABCS-09-3164

E. Ruckhaberle, A. Rody, U. Holtrich, K. Engels, R. Gaetje, H. Turley, L. Hanker, C. Solbach, T. Karn and M. Kaufmann. Correlation of Thymidine Phosphorylase Expression and Lymphocyte Infiltration Detected by Microarray Analysis of Breast Cancer. Cancer Research February 10, 2010 69:2139; doi:10.1158/0008-5472.SABCS-09-2139

A Rody, E Ruckhaeberle, U Holtrich, R Gaetje, K Engels, L Hanker, C Solbach, A Ahr, D Metzler, T Karn, and M Kaufmann. T cell marker metagene predicts a favourable prognosis in estrogen receptor negative and Her2 positive breast cancers.Cancer Research February 19, 2009 69:1048; doi:10.1158/0008-5472.SABCS-1048

E Ruckhaberle, A Rody, R Gaetje, K Engels, U Holtrich, T Karn, and M Kaufmann. Prognostic and predictive value of enzymes of the sphingolipid metabolism in breast cancer. Cancer Research February 19, 2009 69:6014; doi:10.1158/0008-5472.SABCS-6014

A. Rody, U. Holtrich, R. Gaetje, K. Engels, G. von Minckwitz, S. Loibl, M. Gehrmann, E. Ruckhäberle, A. Ahr, C. Solbach, T. Karn, M. Kaufmann. Breast cancer classification according to “stem cell- like” features and its relevance for systemic adjuvant treatment decision. SABCS 2007.

E. Ruckhäberle, T. Karn, S. Schiffmann, S. Grösch, G.Geisslinger, R. Gätje, U. Holtrich, A. Rody, M.Kaufmann. ER dependent regulation of sphingolipid metabolism in the context of apoptosis and proliferation in breast cancer. SABCS 2007.

A. Rody, U. Holtrich , R Gaetje, R. Diallo, V. Muller, M. Gehrmann, K. Engels, G. von Minckwitz, S. Loibl, E. Ruckhaeberle, A. Ahr, C. Solbach, T. Karn M. Kaufmann. Breast cancers with properties of mammary epithelial stem cells delineate endocrine responsiveness. SABCS 2006 #6122.

A. Rody, T. Karn, M. Munnes, G. von Minckwitz, S. Loibl, R Gaetje, C. Solbach, U. Holtrich, M. Kaufmann. Predictive gene signatures for response to neoadjuvant TAC-chemotherapy from expression profiling. SABCS 2005 #5046.

Ahr, A., Holtrich, U., Solbach, C., Scharl, A., Strebhardt, K., Karn, T., Kaufmann , M. Molecular classification of high risk breast cancer patients by gene expression profiling. 23rd Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Tr 2000, 64(1), 134

Ahr, A., Holtrich, U., Solbach, C., Minckwitz, G., Strebhardt, K., Scharl, A., Karn, T., Kaufmann , M. 22nd Annual San Antonio Breast Cancer Symposium: Identification of differentially expressed genes in primary breast carcinoma by cDNA array hybridization Breast Cancer Res Tr 1999, 57 (1), 134.


IMPAKT/ESMO Breast Cancer Conference:

Westhoff CC, Müller SK, Schmatloch S, Henke R-P, Jank P, Hattesohl A, Janni W, Fasching PA, Marmé F, Karn T, Schmidt M, Müller V, Untch M, Schem C, Stickeler E, van Mackelenbergh M, Forstbauer H, Nekljudova V, Loibl S, Denkert C. Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort. ESMO Breast Cancer 2023.
---Abstract: .....

Sinn BV, Untch M, Karn T, van Mackelenbergh M, Huober J, Sychra K, Schmitt W, Marmé F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching PA, Schneeweiss A, Müller V, Nekljudova V, Loibl S, Denkert C. Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome. ESMO Breast Cancer 2022.
---Abstract: .....

Furlanetto J, Marmé F, Thode C, Nekljudova V, Liu Y, Martin M, Reimer T, Knudsen E, Denkert C, Bassy M, Martin L-A, Karn T, Sinn B, Filipits M, van Mackelenbergh M, Fasching PA, Müller V, Stickeler E,Schem C, Loibl S. Impact of body mass index (BMI) on prognosticOvarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B. ESMO Breast Cancer 2022.
---Abstract: .....

Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Müller V, van Mackelenbergh M, Stickeler E, Fasching PA, Schem C, Karn T, Marmé F, Nekljudova V, Loibl S. Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials. ESMO Breast Cancer 2021.
---Abstract: .....

Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, Müller V, Blohmer J-U, Schem C, Engels K, Marmé F, Fissler-Eckhoff A, Fasching PA, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. ESMO Breast Cancer 2021.
---Abstract: .....

Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, Fasching PA, Braun S, Szeto C, Sinn B, van Mackelenbergh M, Schem C, Stickeler E, Soon-Shiong P, Marmé F, Müller V, Untch M, Nekljudova V, Loibl S. BACH1 and HIF1a predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) ESMO Breast Cancer 2021.
---Abstract: .....

Llop-Guevara A, Vladimirova V, Schneeweiss A, Villacampa G, Karn T, Zahm D-M, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Loibl S, Balmaña J, Denkert C, Serra V. Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial ESMO Breast Cancer 2021.
---Abstract: .....

Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Paul Jank P, Huober J, Blohmer J-U, Schmitt WD, Wu S, van Mackelenbergh M, Schem C, Stickeler E, Jackisch C, Untch M, Schneeweiss A, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. ESMO Breast Cancer 2020 Oral Presentation 127O.
---Abstract: Annals of Oncology (2020)
---Webcast: OncologyPro

Karn T, Denkert C, Weber KE, Jank P, El-Balat A, Rody A, Untch M, Loibl S, Pusztai L, Holtrich U. Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. ESMO Breast Cancer 2019 Oral Presentation #344.
---Abstract: Annals of Oncology (2019) 30 (suppl_3): iii1-iii26. 10.1093/annonc/mdz095.

Jank P, Loibl S, Fasching PA, Karn T, Marmé F, Müller V, Schem C, Stickeler E, Lederer B, Denkert C. Influence of PIK3CA mutations on breast cancer proliferation and clinical outcome. ESMO Breast Cancer 2019

Denkert C, Link T, Jank P, Just M, Friedrich K, Hanusch C, Brasch F, von Mackelenbergh M, Küster W, Marmé F, Karn T, Müller V, Kümmel S, Nekljudova V, Loibl S, Blohmer J-U. Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. ESMO Breast Cancer 2019

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L. Immune pruning of genomic heterogeneity in TNBC IMPAKT Breast Cancer Conference 2017. Ann Oncol (2017) 28 (suppl_1): mdx140.002. DOI: 10.1093/annonc/mdx140.002
--- Abstract # 40P: Ann Oncol. 2017. doi:

Sinn BV, Loibl S, Kronenwett R, Furlanetto J, Krappmann K, Karn T, Kerns BJ, Weber K, Schmidt M, Denkert C. Targeted mRNA sequencing of small formalin-fixed and paraffin-embedded breast cancer samples for the quantification of immune and cancer-related genes IMPAKT Breast Cancer Conference 2017. 30P

Stefanie Avril, Gunter von Minckwitz, Katharina Malinowsky, Peter A. Fasching, Thomas Karn, Arndt Hartmann, Michael Untch, Carsten Denkert, Karl-Friedrich Becker, Sibylle Loibl. 24P* Phosphoproteomic assessment of HER2 signaling pathway to stratify anti-HER2 treatment in HER2 non-amplified patients – a translational study in the GeparQuattro and GeparQuinto trials. IMPAKT Breast Cancer Conference 2015. Annals of Oncology 05/2015; 26(suppl 3):iii10-iii10. DOI: 10.1093/annonc/mdv116.02

Gunter von Minckwitz, Berit M. Pfitzner, Volkmar Müller, Petar Fasching, Thomas Karn, Cornelia Liedtke, Christian Schem, Kurt Schönfeld, Thomas Häder, Sibylle Loibl, Carsten Denkert. 21P* Expression of CD138 / Syndecan-1 in triple-negative breast cancer – correlation clinical features and response to chemotherapy in participants of the GeparSixto neoadjuvant study. IMPAKT Breast Cancer Conference 2015. Annals of Oncology 05/2015; 26(suppl 3):iii8-iii8. DOI: 10.1093/annonc/mdv115.09

Oliveira-Ferrer L, Karius T, Witzel I, Karn T, Wirtz RM, Müller V, Milde-Langosch K. 71P* Relevance of glycosylation-associated genes for tumor progression and metastasis localization in breast cancer. IMPAKT Breast Cancer Conference 2015. Annals of Oncology 05/2015; 26(suppl 3):iii23-iii24. DOI: 10.1093/annonc/mdv117.33

Karn T, Sänger N, Ruckhäberle E, Bianchini G, Müller V, Rody A, Solomayer EF, Fehm R, Holtrich U, Becker S. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. IMPAKT Breast Cancer Conference.
--- Abstract # 19P: Ann Oncol. 2014 May;25 Suppl 1:i7. doi: 10.1093/annonc/mdu065.8.

Thomas Karn, Christos Hatzis, Fraser Symmans, Lajos Pusztai, Eugen Ruckhäberle, Marcus Schmidt, Volkmar Müller, Uwe Holtrich, Achim Rody, Manfred Kaufmann. Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (SET). IMPAKT Breast Cancer Conference, Brussels 3-5 May 2012
Oral Presentation --- Abstract # 12O_PR: Ann Oncol (2012) 23 (suppl 2): ii17-ii24 doi:10.1093/annonc/mds039

Thomas Karn, Lajos Pusztai, Eugen Ruckhäberle, Jing Wang, Kevin R. Coombes, Cornelia Liedtke, Lars Hanker, Uwe Holtrich, Achim Rody, Manfred Kaufmann. The Bimodality Index Identifies CT-X Antigens as Poor Prognostic Markers for a Subset of Triple Negative Breast Cancer. IMPAKT Breast Cancer conference, Brussels 2011, 110P.

Liedtke C, Karn T, Gluz O, Wolf M, Holtrich U, Gaetje R, Kiesel L, Kaufmann M, Rody A. The prognostic impact of molecular subtypes remains significant in patients with different age groups. IMPAKT Breast Cancer conference, Brussels 2010.


ASCO - American Society of Clinical Oncology Annual Meeting:

Huebner H, Ruebner M, Schneeweiss A, Denkert C, Sinn HP, Braun M, Karn T, Sinn B, Zahm D-M, Thomalla J, Huober J, Hanusch C, Untch M, Solbach C, Link T, Filmann N, Rey J, Loibl S, Fasching PA. RNA expression levels from peripheral immune cells, a minimal-invasive liquid biopsy source to predict response to therapy and survival in patients with triple negative breast cancer enrolled in the GeparNuevo trial. ASCO Annual Meeting 2023.

Karn T, Denkert C, Rey J, Weber K, Holtrich U, Hanusch C, Sinn B, Jank P, Huober J, Blohmer J, Schmitt WD, van Mackelenbergh M, Schem C, Stickeler, Jackisch C, Untch M, Schneeweiss A, Loibl S. Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple negative breast cancer. ASCO Annual Meeting 2022.
---Abstract: DOI: 10.1200/JCO.2022.40.16_suppl.581

Denkert C, Schneeweiss A, Rey J, Karn T, Braun M, Huober J, Sinn H-P, Zahm D-M, Hanusch C, Marmé F, Furlanetto J, Thomalla J, Blohmer J, van Mackelenbergh M, Staib P, Jackisch C, Fasching PA, Sinn B, Untch M, Loibl S. Biomarkers for response to immunotherapy in triple-negative breast cancer – differences between survival and pCR biomarkers. ASCO Annual Meeting 2022.
---Abstract: .....

Ahmed El-Balat, Uwe Holtrich, Thomas Karn, Sven Becker. FSCN1 as prognostic marker in borderline tumors of the ovary. ASCO Annual Meeting 2020.

Loibl S, Sinn BV, Karn T, Untch M, Sinn HP, Weber K, Hanusch C, Huober J, Staib P, Lorenz R, Blohmer JU, Marmé F, Schmitt WD, Rhiem K, van Mackelenbergh M, Fasching PA, Burchardi N, Higgs B, Schneeweiss A, Denkert C. Whole Exome Analysis oncogenic pathways and TMB in Triple Negative Breast Cancer (TNBC) – Results of the Translational Biomarker Programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. ASCO Annual Meeting 2019.

Seliger B, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J-U, Jackisch C, van Mackelenbergh M, Marmé F, Müller V, Huober J, Untch M, Loibl S, Mueller A, Biehl K, Weber K, Massa C. Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - results from the prospectively randomized GeparNuevo trial. ASCO Annual Meeting 2019.

Denkert C, Link T, Jank P, Just M, Friedrich K, Hanusch C, Brasch F, von Mackelenbergh M, Küster W, Marmé F, Karn T, Müller V, Kümmel S, Nekljudova V, Loibl S, Blohmer J-U. Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. ASCO Annual Meeting 2019.

Aurelia Noske, Karsten Weber, Volker Moebus, Sabine Schmatloch, Wilko Weichert, Claus-Henning Kohne, Christine Solbach, Barbara Ingold Heppner, Katja Steiger, Volkmar Mueller, Peter A. Fasching, Thomas Karn, Marion van Mackelenbergh, Frederik Marme, Wolfgang D Schmitt, Christian Schem, Elmar Stickeler, Carsten Denkert, Sibylle Loibl. Tumor infiltrating lymphocytes predict better DFS from intense dose-dense (idd) EPC regimen – results from the German Adjuvant Intergroup Node-positive Study (GAIN-1). Abstract #226681, ASCO Annual Meeting 2018.

Jenny Furlanetto, Christian Thode, Martina Bassy, Carsten Denkert, Claus Hanusch, Jens Bodo Huober, Christian Jackisch, Sherko Kummel, Andreas Schneeweiss, Michael Untch, Peter A. Fasching, Thomas Karn, Frederic Marme, Marion van Mackelenbergh, Volkmar Müller, Christian Schem, Gunter Von Minckwitz, Dominika Strik, Valentina Nekljudova, Sibylle Loibl. Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC) Abstract #189252, ASCO Annual Meeting 2017.

Borbala Szekely, Anton Safonov, Thomas Karn, Sanaea Baghwagar, Brigid Killelea, Andrea Silber, Christos Hatzis, Lajos Pusztai Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races Abstract #193223, ASCO Annual Meeting 2017.

Mark Wroblewski, Janna-Lisa Velthaus, Raimund Bauer, Volkmar Müller, Christian Schem, Peter A. Fasching, Thomas Karn, Tanja N. Fehm, Thorsten Kühn, Brigitte Kathrin Rack, Carsten Denkert, Michael Untch, Kornelia Kittel, Melanie Janning, Sarah Minner, Guido Sauter, Carsten Bokemeyer, Gunter Von Minckwitz, Sibylle Loibl, Sonja Loges Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. Abstract #191720, ASCO Annual Meeting 2017.

Melanie Janning, Volkmar Müller, Eik Vettorazzi, Miguel Cubas-Cordova, Christine Eulenburg, Christian Schem, Peter A. Fasching, Thomas Karn, Tanja Fehm, Thorsten Kühn, Frank Holms, Friedrich Overkamp, Brigitte Raack, Carsten Denkert, Michael Untch, Klaus Pantel, Carsten Bokemeyer, Sibylle Loibl, Gunter von Minckwitz15 & Sonja Loges1. SERUM CARBONIC ANHYDRASE IX AS PREDICTVE MARKER FOR EFFICACY OF BEVACIZUMAB: A BIOMARKER ANALYSIS FROM THE GEPARQUINTO PHASE III NEOADJUVANT BREAST CANCER TRIAL. Abstract #, ASCO Annual Meeting 2016.

Giampaolo Bianchini, Maurizio Callari, Takayuki Iwamoto, Michela Riba, Lucia Vigano', Alberta Locatelli, Milvia Zambetti, Thomas Karn, Lajos Pusztai, Luca Gianni. Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers. Abstract #149940, ASCO Annual Meeting 2015.

Giampaolo Bianchini, Gabriella Rossi, Maurizio Callari, Takayuki Iwamoto, Eugenia Galeota, Thomas Karn, Catherine Margaret Kelly, Milvia Zambetti, Libero Santarpia, Lajos Pusztai, Luca Gianni. An immune related signature predicts risk of late recurrences beyond proliferation and ER related genes in ER-positive breast cancer. Abstract 530, ASCO Annual Meeting 2014.

Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients. Abstract 1065, ASCO Annual Meeting 2014.

Reinisch M, Grigorieva J, Loibl S, Fasching P, Huober J, Karn T, Liedtke C, Meinhold Heerlein I, Müller V, Rack B, Reimer T, Schem C, Denkert C, Röder H, von Minckwitz G, Untch M. Evaluation of serum mass-spectrometry test in HER2-negative breast cancer patients treated with combination of docetaxel, capecitabine and trastuzumab in the neoadjuvant GeparQuattro trial. ASCO Annual Meeting 2013.

Ruckhäberle E.; Karn T.; Denkert C.; Loibl S.; Ataseven B.; Reimer T.; Hanker L.C.; Sänger N.; Holtrich U.; Kaufmann M., Darb-Esfahani S.; Nekljudova V.; v.Minckwitz G. Predictive value of SphK1- expression in neoadjuvant treatment of breast cancer. ASCO Annual Meeting 2011.

A. Rody, T. Karn, C. Liedtke, E. Ruckhäberle, L. Hanker, R. Gaetje, L. Pusztai, V. Müller, M. Schmidt, U.Holtrich, M. Kaufmann. Clinically Relevant Gene Signatures in Triple Negative and Basal Like Breast Cancer. ASCO Annual Meeting 2010. Poster Discussion #521. J Clin Oncol 28:15s, 2010 (suppl; abstr 521)

L. C. Hanker, T. Karn, B. Linnemann, E. Lindhoff-Last, L. Mavrova, S. Afrashteh, P. Lazarova, R. Gaetje, M. Kaufmann, A. Rody. Clinical risk factors for complications associated with ECG-guided portacath use in breast cancer patients. ASCO Annual Meeting 2010.

Mavrova L, Karn T, Hanker L, Ruckhäberle E, Müller V, Holtrich U, Kaufmann M, Rody A. Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells. ASCO Annual Meeting 2010. J Clin Oncol 28:15s, 2010 (suppl; abstr 661)

Hanker LC, Karn T, Rody A, Ruckhäberle E, Solbach C, Kaufmann M. Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer. ASCO Annual Meeting 2009. J Clin Oncol 27:15s, 2009 (suppl; abstr 566)

A. Rody, U. Holtrich, R Gaetje, Knut Engels, G. von Minckwitz, S. Loibl, Eugen Ruckhäberle, Andre Ahr, T. Karn M. Kaufmann. Contribution of tumor-associated lymphocytes to a niche for "stem cell-like" breast cancer cells. ASCO Annual Meeting 2008.

E. Ruckhäberle, A. Rody, T. Karn, R Gaetje, , M. Gehrmann, U. Holtrich, M. Kaufmann. Prognostic relevance of alterations in sphingolipid metabolism in breast cancer. ASCO Annual Meeting 2008.

A Rody, T Karn, C Solbach, R Gätje, R Diallo, M Gehrmann, G v. Minckwitz, S Loibl, U Holtrich, M Kaufmann. Breast Cancers with stem cell-like features delineate endocrine responsiveness. ASCO Annual Meeting 2007. Poster Discussion. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 10517

A. Rody, U. Holtrich, V. Müller, R. Gaetje, R. Diallo, M. Gehrmann, G. v. Minckwitz, K. Engels, T. Karn, M. Kaufmann. c-kit: identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features. ASCO Annual Meeting 2006.

A. Rody, T. Karn, M. Munnes, G. von Minckwitz, S. Loibl, C. Solbach, U. Holtrich, M. Kaufmann. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. ASCO Annual Meeting 2005, #646.

European Breast Cancer Conference:

A. Rody, U. Holtrich, V. Mueller, K. Engels, G. von Minckwitz, M. Gehrmann, E. Ruckhäberle, C. Solbach, T. Karn, M. Kaufmann. The molecular classification of breast cancer according to the stem-cell model provides important informations for systemic adjuvant treatment decisions. #223, 6th European Breast Cancer Conference 2008. European Journal of Cancer Supplements, Volume 6, Issue 7, April 2008, Page 114

A. Rody, U. Holtrich, E. Ruckhaeberle, R. Gaetje, K. Kourtis, R. Diallo, K. Engels, T. Karn M. Kaufmann. c-kit: identification of coregulated genes in breast cancer patients by gene expression analysis. 5th European Breast Cancer Conference 2006, European Journal of Cancer Supplements, Volume 4, Issue 2, March 2006, Page 143


Other International Talks/Posters:

Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Seliger B, Karn T, Schmatloch S, Schneeweiss A, Sinn B, Fehm T, Denkert C, Litmeyer A-S, Jank P, Furlanetto J, Ortmann O, van Mackelenbergh M, Nekljudova V, Loibl S. Tumor biology and immunology of BCP vs non-pregnant cohort. ESMO 2022. --- Poster: LINK

Hägele M, Müller K-R, Denkert C, Schneeweiss A, Sinn B, Untch M, van Mackelenbergh M, Jackisch C, Nekljudova V, Karn T, Alber M, Marmé F, Schem C, Stickeler E, Fasching PA, Müller V, Weber K, Lederer B, Loibl S, Klauschen F. Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies. ESMO 2022.

Hanker L, El-Balat A, Karn T, Holtrich U, Decker B, Pfisterer J, Gevensleben H, Kommoss S for the AGO study group. ACID CERAMIDASE EXPRESSION (ASAH-1) EXPRESSION IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER. ESGO 2022.

Hanker L, El-Balat A, Karn T, Holtrich U, Decker B, Pfisterer J, Gevensleben H, Kommoss S for the AGO study group. ACID CERAMIDASE EXPRESSION (ASAH-1) EXPRESSION IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER. IGCS 2022.

Karn T. Immune sculpting of the breast cancer genome. TIMO XV 2019

Jenny Furlanetto, Valentina Nekljudova, Andreas Schneeweiss, Christian Thode, Carsten Denkert, Michael Untch, Martina Bassy, Thomas Karn, Peter A. Fasching, Elmar Stickeler, Christian Schem, Frederik Marme´, Eva-Maria Grischke, Marion van Mackelenbergh, Dominika Strik, Sabine Schmatloch, Volkmar Müller, Sibylle Loibl. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). ESMO 2019.

Drosos Z, Gevensleben H, Kommoss S, Karn T, Holtrich U, Graeser-Mayer M, Anglesio M, El-Balat E, Hanker L, Rody A. The prognostic impact of Sphingosine-Kinase 1 expression (SphK1) on ovarian cancer. ESGO 2019.

T. Karn. Who's fighting whom in breast cancer? Relationships between tumor immunoediting and clonal heterogeneity. FEBS Workshop BREAST CANCER RESEARCH: TUMOUR HETEROGENEITY, IMMUNOTHERAPY, AND CELLULAR METABOLISM. Budapest 2018.
--- Organizers: LINK
--- Website: LINK

Massa C, Mueller A, Schneeweiss A, Hanusch C, Huober J, Untch M, Karn T, Fasching P, Marmé F, Burchardi N, Denkert C, Loibl S, Seliger B. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial). European Conference of Immunology (ECI) Sept 2.-5.2018.

Fasching AP, Laible M, Weber K, Wirtz R, Denkert C, Schlombs K, Schmatloch S, Camara O, Lück HJ, Huober J, Karn T, van Mackelenbergh M, Marmé F, Müller V, Schem C, Stickeler E, Sahin U, Loibl S, Untch M. Evaluation of the MammaTyper® as a molecular predictor for response to neoadjuvant chemotherapy (NACT) and outcome in different breast cancer (BC) subtypes European Society of Medical Oncology (ESMO) 2018.

Fasching AP, Laible M, Weber K, Wirtz R, Denkert C, Schlombs K, Schmatloch S, Camara O, Lück HJ, Huober J, Karn T, van Mackelenbergh M, Marmé F, Müller V, Schem C, Stickeler E, Sahin U, Loibl S, Untch M. Validation of the MammaTyper®score as a predictor for response to neoadjuvant chemotherapy in breast cancer European Society of Medical Oncology (ESMO) 2018.

Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt W, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Lehmann A, Jackisch C, Sers C, Schneeweiss A, Fasching P, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational diversity and therapy response in breast cancer – a sequencing analysis in the neoadjuvant GeparSepto trial. AACR 2018.

LC Hanker, Z Drosos, S Kommoss, T Karn, U Holtrich, M Graeser-Mayer, M Anglesio, A El-Balat, H Gevensleben. EXPRESSION OF ACID CERAMIDASE (ASAH1) AS A PROGNOSTIC FACTOR IN OVARIAN CANCER. ESGO 2017.

A El-Balat, Schmeil I, T Karn, U Holtrich, S Becker, K Engels. CLAUDIN 1 EXPRESSION AS A STRATIFICATION MARKER IN BORDERLINE TUMORS OF THE OVARY. ESGO 2017.

Gasimli K, Straussner M, Schmeil I, Becker S, Winkelmann R, Karn T, El-Balat A. IMPACT OF HISTOLOGICAL TUMOR-FREE MARGIN (hTFM) AND RE-EXCISION ON SURVIVAL IN PRIMARY VULVAR CANCER WITH ADJACENT VULVAR INTRAEPITHELIAL NEOPLASIA (VIN III). ESGO 2017.

T. Karn. Dealing with dataset bias in breast cancer genomics. Budapest Breast Think Tank, invited talk, Feb-22 2016.
--- Website: LINK

Linde N, Mortha A, Saenger N, Rahman A, Sosa MS, Harper K, Tardio E, Fehm T, Karn T, Merad M, Aguirre-Ghiso JA. Macrophages orchestrate early dissemination of HER2+ cancer cells. AACR 2016, Abstract 3233. Cancer Research 76(14 Supplement):3233 July 2016

T. Karn. Gene expression, dataset bias, and subtyping of TNBC. Yale University, invited talk, Dec-9 2014.

T. Karn. Prognostic and predictive value of immune cell infiltration in breast cancer. Yale University, invited talk, Dec-9 2014.

Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. Dynamic re-training using case-specific training cohorts outperforms gene expression signatures using fixed gene sets in breast cancer patients. AACR 2014.

T. Karn. The prognostic value of immune infiltration in breast cancer: Any clinical utility for decision making? XIII Michelangelo Seminar 2013, Milan. Invited Talk.
--- Program: LINK
--- Website: LINK

T. Karn. Pre-selection or stratification by biomarkers - what is best ? Neoadjuvant treatment of breast cancer - upcoming challenges, Biedenkopf 2013

Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. The utilization of case-specific training cohorts in a dynamic classification of breast cancer patients outperforms static prognostic gene expression signatures. Hungarian Oncology Association 2013.

T. Karn, A. Rody, C. Liedtke, L. Pusztai, E. Ruckhäberle, L. Hanker, R. Gaetje, C. Solbach, A. Ahr, D. Metzler, M. Schmidt, V. Müller, U.Holtrich, M. Kaufmann. Clinically Relevant Gene Signatures in Triple Negative and Basal Like Breast Cancer. BREAKTHROUGH TRIPLE NEGATIVE BREAST CANCER CONFERENCE, London 2011, A03

Hanker LC, Mavrova L,Karn T,, Ruckhäberle E, Engels K, Holtrich U, Rody A, Kaufmann M. SATB1 gene expression and breast cancer prognosis. 13th Biennial Meeting of the International Gynecologic Cancer Society Prague 2010.

Karn T, Rody A, Holtrich U, Müller V, Ruckhäberle E, Gaetje R, Ahr A, Solbach C, Kaufmann M. Relationship between breast cancers with “stem cell-like” features and endocrine responsiveness. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer 2008, oral presentation.

Ruckhäberle E, Karn T, Gätje R, Metzler D, Holtrich U, Rody A, Kaufmann M. Sphingolipids and Breast Cancer. Vortrag World Menopause Society, Madrid 2008.

Rody A, Karn T, Munnes M, von Minckwitz G, Loibl S, Gaetje R, Solbach C, Holtrich U, Kaufmann M. Gene signatures for response prediction to neoadjuvant TAC chemotherapy. 5th International "From Gene To Cure" Congress, Amsterdam 2006. Oral presentation.

Karn T. Identification of breast cancer patients with high risk of relapse. Key Advances in the Effective Management of Breast Cancer, London 2002, Plenary Lecture.

Karn T, Hock B, Strebhardt K, Rubsamen-Waigmann H. Two Hybrid analysis of the Nef protein of HIV-2D205. Cold Spring Harbor Meet. on Retroviruses 1996.

Karn, T., Kobelt, D., Holtrich, U., Bräuninger, A., Böhme, B., Rübsamen-Waigmann, H. & Strebhardt, K. PLK and MO15, two human serine/threonine kinase genes, seem to be involved in cell cycle control. 10th Ann. Meet. on Oncogenes 1994.

Karn, T., Holtrich, U., Bräuninger, A., Böhme, B., Wolf, G., Strebhardt, K. & Rübsamen-Waigmann, H. TKT, a novel receptor tyrosine kinase, has a unique extracellular domain with homologies to factor VIII like sequences. 9th Ann. Meet. on Oncogenes 1993.

Bräuninger, A., Karn, T., Strebhardt, K. & Rübsamen-Waigmann, H. Genomic organization of CSK represents an intermediate between the SRC family and FES. 8th Ann. Meet. on Oncogenes 1992.


National Meetings: Talks/Posters

Jahrestagung der Deutschen Gesellschaft für Senologie:

Malgorzata Banys-Paluchowski1, Sibylle Loibl2, Isabell Witzel3, Christoph Mundhenke4, Bianca Lederer2, Christine Solbach5, Thomas Karn5, Frederik Marmé6, Valentina Nekljudova2, Christian Schem7, Elmar Stickeler8, Michael Untch9, Volkmar Müller3. Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the GeparQuinto trial. 39. Jahrestagung der Deutschen Gesellschaft für Senologie. 2019.

Thomas Karn: Immuntherapie und Neoantigene in der personalisierten Therapie des Mammakarzinoms. 38. Jahrestagung der Deutschen Gesellschaft für Senologie. 14.-16.6.2018.

Jenny Furlanetto1, Christian Thode2, Jens Huober3, Carsten Denkert4, Martina Bassy2, Claus Hanusch5, Christian Jackisch6, Sherko Kümmel7, Andreas Schneeweiss8, Michael Untch9, Peter A. Fasching10, Thomas Karn11, Frederik Marmé8, Marion van Mackelenbergh12, Volkmar Müller13, Christian Schem12, Gunter von Minckwitz1, Dominika Strik14, Valentina Nekljudova1, Sibylle Loibl1 Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC). 38. Jahrestagung der Deutschen Gesellschaft für Senologie. 14.-16.6.2018.

Thomas Karn: "Neues zur Therapieprädiktion". Vortrag, Sitzung From Bench To Bedside. 32. Jahrestagung der Deutschen Gesellschaft für Senologie. 5.-7.Juli 2012.

Eugen Ruckhäberle, Thomas Karn, Lajos Pusztai, Cornelia Liedtke, Volkmar Müller, Marcus Schmidt, Dirk Metzler, Jing Wang, Kevin R. Coombes, Regine Gätje, Lars Hanker, Andre Ahr, Uwe Holtrich, Achim Rody, Manfred Kaufmann. Assoziation von CT-X Antigen Expression mit schlechter Prognose bei triple-negativem Mammakarzinom. Senolgie 2011 Vortrag.

Ruckhäberle E, Rody A, Karn T, Hanker L, Gätje R; Holtrich U, Kaufmann M. Prognostische Bedeutung der Glucosylceramidsynthase beim Mammakarzinom. Senologie 2010.

Thomas Karn: Stammzelltumoren oder die Stammzelle des Tumors? Vortrag, Senologiekongress 2009.

Achim Rody, Thomas Karn, Eugen Ruckhäberle, Lars Hanker, Dirk Metzler, Volkmar Müller, Christine Solbach, Andre Ahr, Regine Gätje, Uwe Holtrich, Manfred Kaufmann. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers – results of a large scale microarray analysis. Senologiekongress 2009.

Achim Rody, Uwe Holtrich, Regine Gätje, Volkmar Müller, Raihanatou Diallo, Christopher Poremba, Mathias Gehrmann, Knut Engels, Sibylle Loibl, Gunter von Minckwitz, Dirk Metzler, Eugen Ruckhäberle, Andre Ahr, Christine Solbach, Thomas Karn, Manfred Kaufmann. Prognostic and predictive impact of stem cell-like breast cancers. Senologiekongress 2007.


COMBATing Breast Cancer (Conference On Molecular Basics And Therapeutic implications in breast cancer) & AGO-TraFo-Symposium:

T. Karn. "Single Cell Sequencing" Vortrag 11.COMBATing Breast Cancer / 11.Wissenschaftliches Symposium der Kommission Translationale Forschung der Arbeitsgemeinschaft Gynäkologische Onkologie. 11.-12.10.2019

T. Karn. "Grundlagen der Immunologie + ..." Vortrag 10. Wissenschaftliches Symposium der Kommission Translationale Forschung der Arbeitsgemeinschaft Gynäkologische Onkologie. 7.-8.9.2018

T. Karn. Immune Signalling. Vortrag COMBATing Breast Cancer 2016.

T. Karn. Targeting PI3K-Pathway. Vortrag 7. Wissenschaftliches Symposium der Kommission Translationale Forschung der Arbeitsgemeinschaft Gynäkologische Onkologie. 22.-23.10.2015

T. Karn. Bedeutung des Immunsystems für das Therapieansprechen beim Mammakarzinom. Vortrag 6. Wissenschaftliches Symposium der Kommission Translationale Forschung der Arbeitsgemeinschaft Gynäkologische Onkologie. 20.-21.11.2014

T. Karn. Workshop: Molekulare Analysen in der translationalen Forschung. Vortrag 6. Wissenschaftliches Symposium der Kommission Translationale Forschung der Arbeitsgemeinschaft Gynäkologische Onkologie. 20.-21.11.2014

T. Karn. Tumor-stromal interactions. Vortrag COMBATing Breast Cancer 2013.

Ruckhäberle E, Holtrich U, Rody A, Müller V, Schmidt M, Sänger N, Fehm T, Becker S, Karn T. Prognostic Impact of RANK, RANKL, and OPG Gene Expression in ER Positive Breast Cancer. TraFo-Symposium 2013 der AGO.

Liedtke C, Karn T, Gluz O, Holtrich U, Rody A. The prognostic impact of molecular subtypes remains significant in patients with different age groups. TraFo-Symposium 2013 der AGO.

Milde-Langosch K, Karn T, Schmidt M, Wirtz RM, Müller V. Prognostische Bedeutung der Glykosylierung in Mammakarzinomen. TraFo-Symposium 2013 der AGO.

T. Karn. Next Generation Sequencing – Grundlagen und Hürden. Vortrag COMBATing Breast Cancer 2012.

T. Karn. "Wirtsfaktoren" bei Brustkrebs – Gegensätzliche Einflüsse von Immunzellen und inflammatorischen Botenstoffen. Vortrag TraFo-Symposium 2012 der AGO.

T. Karn. Tumor Stroma als therapeutischer Ansatzpunkt? Immunzellen und molekulare Subtypen. Vortrag COMBATing Breast Cancer 2011.

T. Karn. Integration molekularer Tools in die klinische Routine. Vortrag COMBATing Breast Cancer 2010.

T. Karn. Biologische und molekulare Relevanz intrinsischer Gensignaturen: Ist „basal“ wirklich böse? Vortrag COMBATing Breast Cancer 2008.


Jahrestagung der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG):

Hanker L, Drosos Z, Kommoss S, Karn T, Holtrich U, Graeser-Mayer M, Anglesio M, El-Balat A, Gevensleben H. Expression of Sphingosine-Kinase 1 (SPHK1) as a prognostic factor in ovarian cancer. DGGG-Kontress-2018

F Hoellen, A Rody, A Kostara, T Karn, U Holtrich, A El-Balat, M Otto, L Hanker. Expression and impact of TFF3 in epithelial ovarian cancer. DGGG 2016. Geburtshilfe Frauenheilkd 2016; 76 - P022. DOI: 10.1055/s-0036-1592960

A. Rody, U. Holtrich, E. Ruckhaeberle, J. Radosa, I. Juhasz-Boess, E.F. Solomayer, M. Kaufmann, T. Karn. Klinische Relevanz der mit dem triple-negativen Mammakarzinom assoziierten IL-8/B-Zellsignatur in den intrinsischen Subtypen. DGGG München 2012.

R. Gaetje, U. Holtrich, A. Rody, E. Ruckhaeberle, L. Hanker, T. Karn, M. Kaufmann. Analysis of differential gene expression in normal peritoneum and peritoneal tissue of endometriosis patients. DGGG München 2010.

Liedtke C, Karn T, Gluz O, Wolf M, Holtrich U, Gaetje R, Tio J, Kiesel L, Kaufmann M, Rody A. Die ungünstige Prognose von Patientinnen mit tripelnegativem Mammakarzinom nach Stratifikation in Altersgruppen. DGGG München 2010.

Achim Rody, Thomas Karn, Volkmar Müller, Markus Schmidt, Christine Solbach, Regine Gätje, Mathias Gehrmann, Eugen Ruckhäberle, Uwe Holtrich, Manfred Kaufmann. Microarray analysis of differentially expressed genes in luminal B subtype of breast cancers reveals NHERF1 as a new marker of endocrine resistance. DGGG München 2010.

Rody A, Karn T, Pusztai L, Liedtke C, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. A Clinically Relevant Gene Signature in Triple Negative and Basal Like Breast Cancer. DGGG München 2010.

L. C. Hanker, L. Mavrova, T. Karn, E. Ruckhäberle, K. Engels, U. Holtrich, A. Rody, M. Kaufmann. Der prognostische Effekt der SATB1-Expression beim Mammakarzinom korreliert mit dem Östrogen Rezeptor Status. DGGG München 2010.

P. Lazarova, L. C. Hanker, L. Mavrova, T. Karn, U. Holtrich, A. Rody, M. Kaufmann. Klinische Risikofaktoren für das Auftreten von Komplikationen beim Einsatz von Port-Kathetern beim Mammakarzinom. DGGG München 2010.

A. Rody, T. Karn, E. Ruckhaeberle, C. Solbach, U. Holtrich, M. Kaufmann. Validation of Plexin B1 as a prognostic and predicitive marker in gene expression datasets of 1363 breast cancer patients. DGGG Hamburg 2008.

Rody A, Karn T, Ruckhäberle E, Müller V, Gätje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha by microarray analysis is highly prognostic in estrogen receptor (ER)+ breast cancer. Vortrag DGGG Hamburg 2008.

E. Ruckhäberle, A. Rody, G. Geisslinger , U. Holtrich, T. Karn, M.Kaufmann. Die Bedeutung des Sphingolipid-Metabolismus beim Mammakarzinom. DGGG Hamburg 2008.

A. Rody, U. Holtrich, C. Solbach, V. Müller, E. Ruckhäberle, R. Gätje, M. Gehrmann, G. v. Minckwitz, T. Karn, M. Kaufmann. Das Stammzellkarzinom der Mamma: Modell der endokrinen Dysregulation und seine klinische Bedeutung. DGGG Berlin 2006.

Thomas Karn, Achim Rody, Christine Solbach, Katherina Kourtis, Uwe Holtrich, Manfred Kaufmann. Methylierung des ER-ß-Gens korreliert mit der Entwicklung des invasiven Mammakarzinoms. Vortrag DGGG Hamburg 2004.

Ahr, A., Karn, T., Solbach, C., Scharl, A., Strebhardt, K., Holtrich, U., Kaufmann, M. Korrelation von Genexpressionsmustern und TNM-Klassifikation beim primären Mammakarzinom. Vortrag DGGG München 2000.


Deutscher Krebskongress (DKK):

Jenny Furlanetto, Valentina Nekljudova, Andreas Schneeweiss, Christian Thode, Carsten Denkert, Michael Untch, Martina Bassy, Thomas Karn, Peter A. Fasching, Elmar Stickeler, Christian Schem, Frederik Marme´, Eva-Maria Grischke, Marion van Mackelenbergh, Dominika Strik, Sabine Schmatloch, Volkmar Müller, Sibylle Loibl. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). Deutscher Krebskongress 2020.

Ahmed El-Balat, Thomas Karn, Uwe Holtrich, Stefan Kommoss, Balázs Gyorffy, Michael S. Anglesio, David G. Huntsman, Zacharias Drosos, Achim Rody, Lars C. Hanker, Heidrun Gevensleben, Sven Becker. Acid ceramidase adds independent prognostic value to estrogen receptor in endometrioid ovarian cancer. Deutscher Krebskongress 2020.

Ahmed El-Balat, Iryna Schmeil, Thomas Karn, Nicole Sänger, Uwe Holtrich, Knut Engels, Sven Becker. Claudin-1 expression in borderline epithelial tumours of the ovary is linked to implants and micropapillary pattern. Deutscher Krebskongress 2020.

Eugen Ruckhäberle, A. Rody, U. Holtrich, K. Engels, R. Gaetje, H. Turley, LC. Hanker, T. Karn, M. Kaufmann. Die prognostische Bedeutung der Thymidinphosphorylase beim Mammacarcinom. Deutscher Krebskongress 2010.

Rody A, Holtrich U, Gätje R, Müller V, Gehrmann M, Engels K, Loibl S, von Minckwitz G, Diallo R, Metzler D, Ruckhäberle E, Ahr A, Solbach C, Karn T, Kaufmann M. Relevance of stem cell like breast cancers for adjuvant treatment decision. Vortrag Deutscher Krebskongress 2008.

E. Ruckhäberle, T. Karn, S. Schiffmann, S. Grösch, G. Geisslinger, R. Gätje, U. Holtrich, A. Rody, M.Kaufmann. Microarray analysis reveals prognostic significance of altered sphingolipid metabolism in breast cancer. Deutscher Krebskongress 2008.

Karn, T.; Rody, A.; Holtrich, U.; Ruckhäberle, E.; Gätje, R.; Munnes, M.; Gehrmann, M.; Kourtis, K.; Diallo , R.; Engels, K.; von Minckwitz, G.; Kaufmann, M. C-KIT: IDENTIFICATION OF CO-REGULATED GENES IN BREAST CANCER PATIENTS BY GENE EXPRESSION ANALYSIS AND DISCRIMINATION OF TWO BREAST CANCER SUBTYPES WITH STEM-CELL-LIKE FEATURES. Vortrag Deutscher Krebskongress 2006.

Ahr A., Karn T., Seiter S., Solbach C., Strebhardt K., Holtrich U., Kaufmann M. Identifikation von Brustkrebspatientinnen mit hohem Risiko durch Genexpressionsprofile. Vortrag Deutscher Krebskongress 2002.

Ahr, A., Holtrich, U., Solbach, C., Scharl, A., Strebhardt, K., Karn, T., Kaufmann, M. Differentially expressed genes in breast cancer detected by cDNA array hybridization. Vortrag Deutscher Krebskongress 2000.


UCT Science Day Frankfurt:

Denkert C, Karn T, Schneeweiss A, Rey J, Braun M, Huober J, Sinn H-P, Zahm D-M, Hanusch C, Marmé F, Furlanetto J, Thomalla J, Blohmer J, van Mackelenbergh M, Staib P, Jackisch C, Fasching PA, Sinn B, Untch M, Loibl S. Biomarkers for response to immunotherapy in triple-negative breast cancer – differences between survival and pCR biomarkers. UCT Science Day 2022.

Thomas Karn, Carsten Denkert, Bruno V. Sinn, Karsten E. Weber, Valentina Nekljudova, Achim Rody, Tobias Meissner, Christos Hatzis, Ahmed El-Balat, Christine Solbach, Michael Untch, Andreas Schneeweiss, Sibylle Loibl, Lajos Pusztai, Sven Becker, Uwe Holtrich. Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene. UCT Science Day 2019.

Ahmed El-Balat, Thomas Karn, Uwe Holtrich, Stefan Kommoss, Balázs Gyorffy, Michael S. Anglesio, David G. Huntsman, Zacharias Drosos, Achim Rody, Lars C. Hanker, Heidrun Gevensleben, Sven Becker. Acid ceramidase adds independent prognostic value to estrogen receptor in endometrioid ovarian cancer. UCT Science Day 2019.

Thomas Karn, Tobias Meissner, Karsten E. Weber, Bruno Sinn, Carsten Denkert, Jan Budczies, Valentina Nekljudova, Peter A. Fasching, Uwe Holtrich, Christian Schem, Christine Solbach, Arndt Hartmann, Christoph Röcken, Michael Untch, Brandon M Young, Scooter Willis, Brian Leyland-Jones, Gunter von Minckwitz, Sibylle Loibl. A predictor for bevacizumab response from blinded molecular analysis of FFPE-RNA-Seq in the GeparQuinto breast cancer trial. Frankfurt Cancer Conference 2018. P132.

Ahmed El-Balat, Knut Engels, Iryna Schmeil, Khayal Gasimli, Nicole Sänger, Uwe Holtrich, Sven Becker, Thomas Karn. Claudin-1 expression in borderline epithelial tumours of the ovary is linked to implants and micropapillary pattern Frankfurt Cancer Conference 2018. P079.

Thomas Karn, Tingting Jiang, Christos Hatzis, Nicole Sänger, Ahmed El-Balat, Uwe Holtrich, Sven Becker, Giampaolo Bianchini, Lajos Pusztai. Shaping of the cancer genome by the immune system in breast cancer. 7th UCT Science Day 2017.

Thomas Karn, Tingting Jiang, Christos Hatzis, Nicole Sänger, Ahmed El-Balat, Uwe Holtrich, Giampaolo Bianchini, Lajos Pusztai, Sven Becker. Immune sculpting of the triple negative breast cancer genome. 7th UCT Science Day 2016.

Ahmed El-Balat, Irina Schmeil, Thomas Karn, Uwe Holtrich, Ruza Arsenic, Sven Becker. TFF3 expression as stratification marker in borderline epithelial tumors of the ovary. 7th UCT Science Day 2016.

Karn T, Sänger N, Bianchini G, Heinrich T, Holtrich U, Becker S. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer . 6th UCT Science Day 2014.

Karn T, Hatzis C, Symmans WF, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Sänger N, Heinrich T, Rody A, Holtrich U, Sven Becker S. SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. 5th UCT Science Day 2013.

Karn T, Sänger N, Ruckhäberle E, Rody A, Müller V, Schmidt M, Heinrich T, Fehm T, Holtrich U, Becker S. Prognostic Impact of RANK, RANKL, and OPG Gene Expression in ER Positive Breast Cancer. 5th UCT Science Day 2013.

Thomas Karn, Lajos Pusztai, Eugen Ruckhäberle, Jing Wang, Kevin R. Coombes, Cornelia Liedtke, Lars Hanker, Uwe Holtrich, Achim Rody, Manfred Kaufmann. The Bimodality Index Identifies CT-X Antigens as a poor prognostic marker for a Subset of Triple Negative Breast Cancers. 3rd UCT Science Day 2011.

Ruckhäberle E.; Karn T.; Denkert C.; Loibl S.; Ataseven B.; Reimer T.; Hanker L.C.; Sänger N.; Holtrich U.; Kaufmann M., Darb-Esfahani S.; Nekljudova V.; v.Minckwitz G. Predictive value of SphK1- expression in neoadjuvant treatment of breast cancer. UCT Klinischer Forschungstag 2011.

T. Karn, A. Rody, C., Liedtke, E. Ruckhäberle, L. Hanker, R. Gaetje, L. Pusztai, V. Müller, M. Schmidt, U.Holtrich, M. Kaufmann. Clinically Relevant Gene Signatures in Triple Negative and Basal Like Breast Cancer. 2nd UCT Science Day 2010.

Ruckhäberle E., Karn T., Hanker LC., Schwarz J., Schulz-Knappe P., Kuhn K., Engels K., Hansmann ML., Holtrich U., Rody A., Kaufmann M. Tandem Mass Tag Technology- a helpful tool for proteomic research in breast cancer? 2nd UCT Science Day 2010.

T. Karn, A. Rody, D. Metzler, E. Ruckhaeberle, L. Hanker, R. Gaetje, K. Engels, C. Solbach, A. Ahr, M. Schmidt, V. Müller, U. Holtrich, M. Kaufmann. Meta-Analysis of a pool of 3030 Affymetrix arrays from breast cancers: Stem cell like-tumors delineate endocrine responsiveness. UCT Science Day 2009.

L. C. Hanker, T. Karn, A. Rody, E. Ruckhäberle, K. Engels, U. Holtrich, C. Solbach, M. Kaufmann. Gene expression of p63 by microarray analysis is highly prognostic in estrogen receptor positive breast cancer. UCT Science Day 2009.

A. Rody, T. Karn, C. Solbach, E. Ruckhäberle, L. Hanker, A. Ahr, R. Gätje, U. Holtrich, M. Kaufmann. The Luminal B marker NHERF1 predicts endocrine resistance in breast cancer. UCT Science Day 2009.

E. Ruckhäberle, A. Rody, U. Holtrich, K. Engels, R. Gaetje, L. Hanker, C. Solbach, A. Ahr, T. Karn, M. Kaufmann1. Correlation of thymidine phosphorylase expression and lymphocyte infiltration detected by microarray analysis of breast cancer.UCT Science Day 2009.

Other National Meetings:

T. Karn. Workshop Immunologie. GBG-Jahrestreffen 2023.

T. Karn. Translationale Projekte zur Immunoonkologie. GBG-Jahrestreffen 2022.

T. Karn. Translationale Projekte zur Immunoonkologie. GBG-Jahrestreffen 2021.

T. Karn, B. Sinn. Workshop Immunologie. GBG-Jahrestreffen 2020.

T.Karn: Was ist Was - Immuntherapie. 14. Bad Kreuznacher Fortbildung Brustkrebs 2020.

Sinn BV, Loibl S, Karn T, Untch M, Treue D, Sinn HP, Weber K, Klauschen F, Hanusch C, Liebscher C, Wagner K, Fasching PA, Huober J, Zahm M, Jackisch C, Thomalla J, Blohmer JU, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Expression von PD-L1 und dynamische Veränderungen tumor-infiltrierender Lymphozyten bei neoadjuvanter Chemotherapie mit Immun-Checkpunkt-Blockade beim frühen triple-negativen Mammakarzinom Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP) 2019.

T. Karn. Immunologie-Workshop. GBG-Jahrestreffen 2019.

T. Karn. Immunologie-Workshop. GBG-Jahrestreffen 2018.

Sinn BV, Loibl S, Kronenwett R, Furlanetto J, Krappmann K, Karn T, Kerns BJ, Weber K, Schmidt M, Denkert C. Targeted mRNA sequencing using small formalin-fixed, paraffin-embedded core biopsies to evaluate immune- and tumor-associated gene expression in breast cancer. Jahrestagung der Deutschen Gesellschaft für Pathologie 2018.

Sinn BV, Weber K, Denkert C, Fasching PA, Schmitt WD, Karn T, Taube E, van Mackelenbergh M, Symmans WF, Marmé F, Kunze CA, Müller V, Villegas-Angel SL, Schem C, Stickeler E, von Minckwitz G, Loibl S. Expression of MHC class I in breast cancer: association with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy. Jahrestagung der Deutschen Gesellschaft für Pathologie 2018.

T. Karn. Immunologie-Workshop. GBG-Jahrestreffen 2017.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G & Loges S. SERUM CARBONIC ANHYDRASE IX AS PREDICTIVE MARKER FOR EFFICACY OF BEVACIZUMAB: A BIOMARKER ANALYSIS FROM THE GEPARQUINTO PHASE III NEOADJUVANT BREAST CANCER TRIAL. Jahrestagung der DGHO, OeGHO, SGMO und SGH 2016.

S. Avril, G. von Minckwitz, K. Malinowsky, S. Gade, S. Gündisch, P. Fasching, T. Karn, A. Hartmann, M. Untch, C. Denkert, K.-F. Becker, S. Loibl. Functional pathway activation mapping to stratify anti-HER2 treatment in HER2 non-amplified breast cancer. Vortrag Gemeinschaftstagung der Deutschen Gesellschaft für Pathologie und der Deutschen Gesellschaft für Zytologie. 28.-30.5.2015

T. Karn. Translational Research in Breast and Gynecological Cancers. Vortrag KFG-Retreat Rüdesheim 23.9.2014

E. Ruckhäberle, T. Karn, K. Engels, A. Rody, R. Gaetje, L. Hanker, N. Sänger, U. Holtrich, M. Kaufmann. Die prognostische und prädiktive Bedeutung der Sphingolipide beim primären Mammakarzinom. Wissenschaftliche Hochschullehrertagung 2011.

Ruckhäberle E, Rody A, Karn T, Gätje R; Holtrich U, Kaufmann M. Prognostische Bedeutung der Glucosylceramidsynthase beim Mammakarzinom. MGGG 2008.

Rody A, Holtrich U, Gaetje R,Diallo R, Muller V, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Ruckhaeberle E, Ahr A, Solbach C, Karn T, Kaufmann M. Breast cancers with properties of mammary epithelial stem cells delineate endocrine responsiveness. 14th International AEK Congress.

T. Karn, A. Rody, U. Holtrich, R. Gätje, K. Engels, G. von Minckwitz, S. Loibl, E. Ruckhäberle, A. Ahr, C. Solbach, M. Kaufmann. Poor outcome in estrogen receptor positive breast cancers predicted by loss of Plexin B1 the receptor for growth repelling semaphorin 4D. 14th International AEK Congress.

T. Karn, A. Rody, G. von Minckwitz, S. Loibl, R. Gaetje, C. Solbach, U. Holtrich, M. Kaufmann. Predictive gene signatures for response to neoadjuvant TAC-chemotherapy from expression profiling. 14th International AEK Congress.

T. Karn, U. Holtrich, G. von Minckwitz, S. Loibl, D. Metzler, R. Gätje, C. Solbach, E. Ruckhäberle, A. Rody, M. Kaufmann. “Stem Cell Like” breast cancers allow the identification of novel markers for disturbed estrogen response. 14th International AEK Congress.

A. Rody, U. Holtrich, R. Gätje, R. Diallo, V. Müller, M. Gehrmann, K. Engels, G. v. Minckwitz, E. Ruckhäberle, A. Ahr, C. Solbach, T. Karn, M. Kaufmann. Mammakarzinome mit stammzell-ähnlichen Eigenschaften: Modell für die Analyse endokriner Dysregulationsmechanismen. MGGG 2007

A. Rody, T. Karn, C. Solbach, K. Kourtis, S. Loibl, G. v. Minckwitz, U. Holtrich, M. Kaufmann. Methylierung des ER-ß-Gens korreliert mit der Entwicklung des invasiven Mammakarzinoms. MGGG 2005.

E. Ruckhäberle, A. Rody, T. Karn, M. Munnes, C. Solbach, G. v. Minckwitz, S. Loibl, R. Gätje, U. Holtrich, M. Kaufmann. Genexpressionsprofile von Mammakarzinomen vor einer primär systemischen Chemotherapie: Konkordanz mit Routinemarkern und Identifikation prädiktiver Signaturen. MGGG 2005.

T. Karn. Genomics und Epigenomics. Vortrag Biedenkopf-Meeting zur Translationalen Forschung in der Gynäkologie 2005.

Karn, T., Ahr, A., Seiter, T., Holtrich, U., Kaufmann, M. Clinical application of the microarray technology: Identification of breast cancer patients with high risk of relapse. DECHEMA-Statusseminar Chiptechnologien 2002.

Karn, T., Holtrich, U., Solbach, C., Scharl, A., Strebhardt, K., Ahr, A., Kaufmann, M. Molecular classification of breast cancer patients by gene expression profiling. Vortrag DECHEMA-Statusseminar "Chiptechnologie: Vom Genom zum Proteom" 2001.

Karn, T., Holtrich, U., Ahr, A., Solbach, C., Strebhardt, K., Scharl, A., Kaufmann, M. Expression profiling of primary breast carcinomas by cDNA array hybridization. Vortrag DECHEMA-Statusseminar "DNA-Chiptechnologie" 2000.

Ahr, A., Holtrich, U., Karn, T., Solbach, C., v.Minckwitz, G., Scharl, A., Strebhardt, K. & Kaufmann, M. Geburtshilfe und Frauenheilkunde 1999, 59, 301.

Rübsamen-Waigmann, H., Karn, T. & Strebhardt, K. Die Molekularbiologie der Replikation von HIV. Deutscher AIDS-Kongreß 1996.



Publications

Thomas Karn


Prof. Dr. phil. nat. Thomas Karn
Klinikum der J. W. Goethe-Universität
Theodor-Stern-Kai 7
60590 Frankfurt
t.karn@em.uni-frankfurt.de 		ORCID Record
0000-0002-3264-6573

Researcher ID
AAE-7723-2019
Google Scholar